THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Functional Immune Anatomy of the Liver - as an allograft

Citation for published version:

Demetris, AJ, Bellamy, C, Gandhi, CR, Prost, S, Nakanuma, Y & Stolz, DB 2016, 'Functional Immune Anatomy of the Liver - as an allograft', *American Journal of Transplantation*.
<https://doi.org/10.1111/ajt.13749>

Digital Object Identifier (DOI):

[10.1111/ajt.13749](https://doi.org/10.1111/ajt.13749)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

American Journal of Transplantation

Publisher Rights Statement:

Author's final peer-reviewed manuscript as accepted for publication

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Functional Immune Anatomy of the Liver - as an allograft

By

Demetris¹, A.J, Bellamy², C.O.C., Gandhi³, C.R., Prost², S., Nakanuma⁴, Y., Stolz⁵, D.B.

¹Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA;

²Department of Pathology, University of Edinburgh, Scotland; ³Department of Pediatrics, Cincinnati Children's Hospital Medical Center and Department of Surgery, University of Cincinnati; Cincinnati, Ohio; ⁴Department of Diagnostic Pathology, Shizuoka Cancer Center, Shizuoka, Japan; ⁵Center for Biologic Imaging, Cell Biology, University of Pittsburgh, Pittsburgh, PA

Key words:

Abbreviations: APC: antigen presenting cell; BEC: biliary epithelial cells; DC: dendritic cells; DCD: donation after cardiac death; DSA: donor-specific antibodies; ECD: extended criteria donor; HA: hepatic artery; HABR: hepatic arterial buffer response; HBV: hepatitis B virus; HCV: hepatitis C virus; HMS: hepatic microcirculatory unit; HSC: hepatic stellate cells; LSEC: liver sinusoidal endothelial cells; KC: Kupffer cell; MAMP: microbial-associated molecular patterns; MHC: major histocompatibility complex; MPS: mononuclear phagocytic system; NK: natural killer; PCP: peribiliary capillary plexus; PCS: post-capillary sinus; TCMR: PFbs: portal fibroblasts; PV: portal vein; T cell-mediated rejection; TLR: toll-like receptors;

ABSTRACT

The liver is an immunoregulatory organ in which a tolerogenic microenvironment mitigates the relative “strength” of local immune responses. Paradoxically, necro-inflammatory diseases create the need for most liver transplants. Treatment of HBV, HCV, and acute TCMR have redirected focus on long-term allograft structural integrity. Understanding of insults should enable decades of morbidity-free survival after liver replacement because of these tolerogenic properties.

Studies of long-term survivors show low-grade chronic inflammatory, fibrotic and microvascular lesions, likely related to some combination of environment insults (i.e. abnormal physiology), donor-specific antibodies, and T cell-mediated immunity. The resultant conundrum is familiar in transplantation: adequate immunosuppression produces chronic toxicities, while lightened immunosuppression leads to sensitization, immunological injury, and structural deterioration. The “balance” is more favorable for liver than other solid organ allografts. This occurs because unique hepatic immune physiology and provides unintended benefits for allografts by modulating various afferent and efferent limbs of allogenic immune responses.

This review is intended to provide a better understanding of liver immune microanatomy and physiology and thereby: a) the potential structural consequences of low-level, including allo-antibody-mediated injury; and b) how liver allografts modulate immune reactions. Special attention is given to the microvasculature and hepatic mononuclear phagocytic system (MPS).

INTRODUCTION

The liver is an immunoregulatory organ (1-5) in which a tolerogenic microenvironment mitigates the relative “strength” of local immune responses. Paradoxically, necro-inflammatory diseases still create the need for most liver transplants. Effective anti-HBV(6, 7) and anti-HCV(8, 9) medications and control of acute TCMR have, or will shortly, largely eliminate the negative impact of these insults, redirecting therapeutic focus toward long-term allograft structural integrity. Perhaps a better understanding of unaddressed insults will widely enable decades of morbidity-free survival after liver replacement.

Indeed, emerging evidence shows low-grade chronic inflammatory, fibrotic and microvascular lesions, which are likely related to some combination of environment insults (i.e. abnormal physiology), donor-specific antibodies (DSA), and T cell-mediated immunity, are associated with suboptimal immunosuppression and chronically threaten architectural integrity. The resultant conundrum is familiar in transplantation (reviewed in (10)): adequate immunosuppression reliably produces chronic toxicities, while lightened immunosuppression often leads to sensitization, immunological injury, and structural deterioration. The “balance”, however, is substantially more favorable for liver than other solid organ allografts.

Liver immunology (1-5, 11, 12) and liver allograft “tolerogenicity” (13-15) are the subject of excellent recent reviews, but two areas remain incompletely addressed: the biliary tree and antibodies as immunological effectors and modulators, included herein.

IMPORTANT DIFFERENCES BETWEEN LIVER AND OTHER SOLID ORGAN ALLOGRAFTS

- 1) The liver can be viewed as two inter-dependent organs with a dual afferent blood supply:
 - a. biliary tree: “centrally-placed” tissue whose health is critical to parenchymal integrity. Supplied by arterial blood draining into a typical capillary network, which like kidney and heart, is susceptible to ischemic and immunological insults(Figure 1).
 - b. hepatic parenchyma: the bulk of liver mass which envelops the biliary tree and contributes greatly to tolerogenicity. Supplied by partially de-oxygenated low pressure portal venous blood, rich in intestinal bacterial products and pancreatic hormones, feeds into a unique sinusoidal bed(Figure 2).
- 2) Constant exposure to intestinal microbial products fosters a “tolerogenic” microenvironment with relatively low co-stimulatory and MHC class II expression on antigen presenting cells (APC), including the endothelium (2, 5, 12, 16, 17).
- 3) Sinusoids are the majority microvasculature, lined by LSEC and KC (2, 5, 12, 16-19), which scavenge particulates/antigens, and regulate immune responses (2, 5, 12, 16-18, 20-22), liver regeneration(23-25), and fibrogenesis(25, 26).
- 4) Tremendous parenchymal regenerative abilities include collagenase-mediated matrix remodeling (24, 27), which can reverse fibrosis (28, 29) after elimination of immune injury. This is not observed with other solid organ allografts(30).

- 5) A variety of immune leukocytes (classical T and B cells, NK, NKT, and $\gamma\delta$ -T cells(31, 32)) are normal hepatic inhabitants, including hematopoietic stem cells (33, 34).

HEPATIC ARTERIAL BLOOD SUPPLY AND THE BILIARY TREE

More than seven arteries supply different bile duct territories, including the cystic, posterior superior pancreatico-duodenal, right and left hepatic, and retro-portal collectively providing 95% of arterial blood(35). Arteries encase the biliary tree as far as the peripheral branches, like ground vines around tree trunks(Figures 1 and 2). Flow is regulated by systemic pressure and intra-hepatic resistance vessels including pre-capillary sphincters (36, 37). Typical of splanchnic arterial systems, three anastomotic patterns occur on bile duct walls: a network, a longitudinal anastomotic chain, and an arterial circle(35).

Intra-hepatic portal tract hepatic artery branches divide into axial (accompanying) vessels (38, 39) that branch into peribiliary (connecting) arterioles (38, 39). These taper to form the peribiliary capillary plexus (PCP), which supplies bile ducts(38, 39) (Figure 2). The axial arteries also send capillary branches to: a) portal connective tissue; b) portal vein vasa vasorum; c) direct arterioportal anastomoses alongside septal venules supplying the lobules, from which regular short oblique arterioles enter the adjacent venule or sinusoids (panel 2 Figure 2) (38, 40); and d) isolated arteriolar branches that perforate deep into lobules, possibly supplying hepatic vein vasa vasorum and the liver capsule(41).

The PCP has 2 - 3 well-developed layers in large intrahepatic/extrahepatic bile ducts (42): inner, mostly afferent, subepithelial capillaries (like renal peritubular and cardiac interstitial capillaries); an intermediate and an outer, mostly efferent, layer (43) (Figures 1 and 2). Outer PCP layers end in post-capillary sinuses (PCS) - slightly dilated endothelial conduits linking to sinusoids and portal vein branches (38, 39). PCP layers become ill-defined in smaller interlobular (<100 μ m) bile ducts and attenuate to scattered capillaries: smaller interlobular bile ducts and ductules are accompanied by up to three CD34+ capillaries within <15 μ m from the basement membrane (42, 44).

Arterial/PCP insufficiency causes ischemic cholangiopathy(45-47). Deep PCP injury before transplantation predicts post-transplant biliary strictures in extra-corporally perfused livers(48-50). Chronic biliary disease(44) and chronic rejection(51, 52) reduce axial, connecting artery and PCP density around small interlobular (< 100 μ m) bile ducts, analogous to heart and kidney allografts(53-55). Their destruction likely reflects imbalances between pericyte and endothelial cell repair (56, 57).

The Hepatic Artery Buffer Response (HABR) (Figure 3; HABR) refers to the reciprocal regulation between portal venous and hepatic artery flow. It is independent of innervation and normally suppressed by normal portal venous flow "washout" of the locally-produced major mediator and vasodilator, adenosine. Adenosine washout maintains physiological arterial constriction (58-61). Other mediators, such as nitric oxide, carbon monoxide, and H₂S are also likely HABR contributors (58, 59). Portal venous flow reduction (less washout), usually because of sclerotic occlusion, causes arterial dilation and compensatory increased lobular arterial blood flow via direct arterial conduits and arterio-venous anastomoses at lobular edges or arterial supply to lobules, discussed above. Interestingly, adenosine also can inhibit lymphocyte activation and/or promote Treg expansion(62). Chronic arterial compensation sustains hepatocyte viability/growth

causing nodularity, or nodular regenerative hyperplasia, common in long-surviving liver allografts(63). Conversely, portal venous hyperperfusion in small-for-size livers causes arterial vasospasm/constriction(58, 61). By contrast, reduced arterial perfusion does not alter venous flow, which is driven by splanchnic venous return.

BILIARY TREE

The centrally-placed biliary tree, lined by a single layer of biliary epithelial cells (BEC) under hormonal and neural control, is an excretory conduit for hepatocyte-synthesized bile, excretes enzymes and mucins, and modulates bile water content and composition (64, 65), which contains bile salts (61%) needed for fat emulsification/absorption; fatty acids (12%), cholesterol (9%), phospholipids (3%), bilirubin (3%), >250 proteins (7%), and other endogenous and exogenous compounds, including bio-transformed drugs (66, 67). BEC HCO_3^- secretion normally maintains an alkaline pH preventing the uncontrolled permeation and damage from hydrophobic bile salts, discussed below(68). Despite its importance to parenchymal health and participation in innate and adaptive immune responses (69-71), the biliary tree is usually overlooked in comprehensive liver immunology reviews (1-4, 11, 12). However, the high incidence (~20%) of complications (72-75) and susceptibility to AMR-mediated PCP damage (76-78) mandate greater attention in this review.

Intra-hepatic and hilar/extra-hepatic biliary tree development from hepatoblasts and hepatic diverticulum, respectively, is closely linked with arterial/PCP development(79), fusing into a seamless drainage conduit prior to birth (42, 79, 80). BEC and hepatocytes serve as progenitors for the intra-hepatic biliary epithelium(81, 82); extra-hepatic BEC renewal appears to depend on residual BEC and stem cells at the base of peribiliary glands(49, 83-85).

Secretory immunoglobulin A (sIgA) (86), synthesized by plasma cells near bile ducts (87, 88) dominates bile immunoglobulins (89), but IgG and IgM are also present (90, 91). They neutralize pathogens and bacterial toxins (92); complex with free antigens, facilitating excretion thereby reducing systemic responses (93, 94); and bind intracellular pathogens during transcytosis(95).

BEC possess an array of anti- $\square$ microbial defenses, such as lactoferrin and lysozyme from peribiliary glands (96); defensin(97), cathelicidin(98, 99) and human β -defensin 1 (hBD $\square$ 1). Trefoil family factor proteins protect BEC by increasing mucous viscosity in large bile ducts and peribiliary glands(100 $\square$ 103). Others are inducible(104 $\square$ 106), such as hBD $\square$ 2 in large bile ducts after infection (107). Some innate defenses also modulate adaptive immunity by recruiting CD4+ T cells and immature dendritic cells(108).

BEC also express TLR (71) whose ligation triggers cytokine elaboration to recruit and activate T-cells, macrophages, and NK cells. Human BEC also constitutively express IL-8 and MCP-1 (109-112) - important chemotaxins for neutrophils, monocytes, and T cells – and further upregulate these after endotoxin (via TLR4) or inflammatory cytokine exposure (although IFN- γ inhibits IL-8 production). These and other inflammatory cytokines increase BEC immune “visibility” by increasing constitutive ICAM-1, LFA-3, MHC I and II (70, 71, 113-118) and the molecular machinery for non-professional APC functions, including co-stimulators CD80/CD86 (70, 117-120). This enables BEC to elicit recall responses in primed T cells (116, 121, 122), but not naive T-cell activation (123). Some dampening of immune responses is also possible as PDL1 and PDL2 are also induced by IFN- γ (124).

Ischemic, immunological, and technical insults damage BEC and bile ducts (21, 125, 126). Preservation/reperfusion injury in DCD and ECD donors cause PCP microvascular thrombosis and ischemia (127-129). Re-oxygenation causes more damage than hypoxic injury (130), which enhances BEC TRAIL-mediated apoptosis (131). Immunological injuries include direct cytotoxic lymphocytic damage and indirect ischemic damage from disruption of the PCP by DSA or isoagglutinins (78, 130, 132-137). Pathogenic mechanisms involved in antibody-mediated PCP damage are similar to those described for kidney and heart allografts (138, 139). BEC apoptosis can be autocrine, paracrine and/or leucocyte-mediated (TNF- α , Fas/FasL, TNF-related apoptosis-inducing ligand (TRAIL)) (140-145), but susceptibility can be further modulated by bcl-2 family members.

Inner PCP destruction and local micro-environmental disruption likely account for poor BEC wound healing (74, 146) resulting in ischemic cholangiopathy (reviewed in (74, 147-149)). Necrotic BEC and senescence-associated secretory phenotypes (SASPs) (150) impede wound healing by promoting inflammation and subsequent stricturing (151, 152). Suboptimal BEC regeneration might also contribute (72, 153, 154).

Bile composition influences wound healing: hydrophobic bile salts at low concentrations elicit BEC ROS resulting in apoptosis (72) and necrosis (155); conversely, hydrophilic bile salts (e.g. ursodeoxycholic acid (UDCA)) protect BEC from hydrophobic bile salt-induced injury (reviewed in (155)). UDCA improves liver injury test profiles and the incidence of early biliary tract complications (156, 157). Ischemic injury also impairs HCO_3^- secretion (130, 131, 136, 158) increasing susceptibility to hydrophobic bile salt injury.

PORTAL VENOUS BLOOD SUPPLY AND THE “TOLEROGENIC” PARENCHYMA

Large proximal conducting portal veins (>0.3mm diameter) give rise to smaller hierarchically branching parenchymal/distributing veins responsible for substance exchange with hepatocytes and maintaining liver microarchitecture (159, 160). The conducting, but not the parenchymal, portal vein branches are mirrored with corresponding hepatic veins that drain sinusoids into inferior vena cava (160).

Parenchymal veins follow a strict branching pattern: each first order branch supplies $\sim 1\text{mm}^3$ venocentric parenchymal mass and begets 11 perpendicular, second-order branches that lie in terminal portal tracts on light microscopy (the classic portal triad (159)). These branches outnumber hepatic vein branches 6:1, creating the “classic” hepatic lobule (Figure 2) demarcated by portal tracts at vertices of a hexagon surrounding a central vein. Afferent portal venous blood periodically exits portal tracts to travel along the hexagon edges in *septal venules*. Together they align successively as seams across a curtain of intervening anastomosing sinusoids along an interlobular “vascular septum” (159, 160) from whose face blood flows towards the hepatic veins (Figure 2).

Venous blood first enters the vascular septum sinusoids at right angles from the septal venules through short CD34+ *inlet venules*, which retain a classical basement membrane. The hepatic microcirculatory subunit (MHS), cholehepaton, or primary lobule is the functional nephron equivalent (161): a hepatocyte cone supplied by one inlet venule and draining bile into one bile duct (Figure 2) (159, 161, 162). Flow from inlet venules feeds a distributing network of sinusoids (see (Figure 2a)) (septal zone of inflow, sandwiched between consecutive septal venules). From that inflow zone surface (estimated at 1.7 m^2 total) the distributed flow enters the

remainder of the lobule like a “wave front” into radial sinusoids (Figure 2b) to exit the lobule at terminal hepatic veins.

Sclerosis of portal, septal, and/or inlet venules may be attributable to chronic immunosuppression(63), DSA(135, 163, 164), or other insults, often manifests as NRH(63) via the HABR, in long-surviving grafts(165, 166). Portal inflammation with “interface hepatitis” associated with de novo DSA in long-surviving liver allograft recipients(135, 163, 164, 167) might represent mononuclear septal or inlet venulitis, but work is needed to mechanistically clarify the association.

Liver Sinusoidal Endothelial Cells (LSEC)

LSEC comprise ~50% of non-parenchymal liver cells and channel blood from portal vein branches into “central veins” – the smallest efferent hepatic veins. They interface between sinusoidal content and Disse’s space (Figure 4), into which they regulate leukocyte transmigration with induction of adhesion molecules. Transcellular fenestrations (*fenestrae*, Latin for window; average ~100 nm in diameter): a) are arranged in distinct groups (sieve plates); b) occupy ~6-10% of the surface area (168); c) lack diaphragms, or proteinaceous “screens” that create a selectively permeable barrier to particulates; and d) change size/diameter to modulate bidirectional flow of particulates (e.g. chylomicron remnants and lipoproteins), cells or cell processes(5). LSEC renew from local expansion of liver-based progenitors and bone marrow precursor recruitment after severe injury or partial hepatectomy(23).

Steady state LSEC express vascular (e.g. CD31, vWF^{negative to low}, Ulex lectin binding, and CD105(169)) and lymphatic endothelial markers (CD31, LYVE-1, VAP- 1, and Reelin) (169, 170), generate lymph(171), and lack a typical basement membrane. LSECs also show innate and adaptive immune responsiveness, expressing multiple TLR, MHC I and II (normally at low levels), co-stimulatory molecules (CD80, CD86) and adhesion molecules (ICAM-1) (reviewed in (5)). LSEC internalize soluble antigens, immune complexes and other particulates (5, 172-174), which enables them to compete with DC for pathogen monitoring (reviewed in (5, 17)). In steady state or mild injury, cross-presentation of blood-borne antigens can cross-tolerize CD8+ T cells and promote expansion of regulatory T cells (5, 17). Conversely, innate danger signals (viral RNA, CpG DNA, activated complement, FcR engagement) can override “tolerogenic” tendencies, switching LSEC to recruit and directly stimulate CD8+ and CD4+ effector T cells (5, 17). They also have the potential to influence liver regeneration and fibrosis(12, 17, 23, 25, 26, 175).

Injury (26, 176-180), fibrogenesis (26, 169, 176, 178), and aging (181-183) cause LSEC changes referred to as “(pseudo-)capillarization” including defenestration, basement membrane deposition (type IV collagen, laminin, and fibronectin(178, 184, 185)), antigenic modulation (neo-expression or upregulation of CD31, CD34, vWF), inability to quiet stellate cell activation(23, 26, 177), altered hepatic lipid processing(175), and impaired cell-cell communication(26, 175, 177, 178). Immunohistochemical monitoring in operationally tolerant liver allograft recipients(186) can detect early LSEC changes, such as capillarization and nearby SMA+ SC activation, before more significant damage occurs (185-187).

Lymphatic Flow: The liver is the largest lymph producer: ~25-50% of thoracic duct lymph(188) accepting fluid from portal, sublobular, and capsular networks (171, 188-191). Most lobular lymph is initially formed in Disse’s space with a smaller PCP contribution (~10%) (171, 188-191) moving toward portal tracts(171, 189, 192)

where protruding collagen fibers delineate conduits to intra-portal terminal lymphatic capillaries (171) (Figures 2 and 4). Terminal lymph capillaries lack a continuous basement membrane, similar to LSEC, and are lined by endothelial cells that: a) express numerous but non-exclusive markers, (reviewed in (171, 193)); b) are anchored to surrounding collagen and elastin fibers (171); and c) facilitate fluid and cell entry via specialized intercellular junctions that restrict reflux (171, 188-191, 194). These coalesce into muscular conducting vessels that empty into hilar lymph nodes (171, 188-191). Perivenular lymph likely travels along similar collagen bundles (171, 188-190, 192, 194) into terminal lymphatic capillaries in sublobular vein walls that drain into subdiaphragmatic nodes (171, 189, 190, 192) (see below).

Lymphatic ligation at transplantation initially results in intra-peritoneal DC-rich chylous leakage (1-3 liters/day) then directed to regional diaphragmatic nodes (195). Lymphatic drainage spontaneously regenerates after some months (196), but the effect on DC activities is unknown.

Hepatic Veins: This post-sinusoidal drainage system accepts sinusoidal blood beginning at terminal hepatic veins/venules or central veins located at the center of the lobular hexagon. Progressive coalescence of branches mimicking conducting, but not distributive, portal veins produces the classical lobule. These drainage conduits are targeted in both TCMR and AMR, perhaps related to local DC and terminal lymphatics (197, 198).

MAJOR BLOOD GROUP AND HISTOCOMPATIBILITY COMPLEX ANTIGEN EXPRESSION AND ORGAN CHIMERISM

Recognition that de novo anti-MHC DSA can decrease graft survival, especially when inflammatory comorbidities like recurrent HCV exist renewed interest in MHC antigen expression (76, 199-201). Cataloging tissue MHC antigen expression and organ composition/chimerism after transplantation demonstrates potential targets for anti-MHC DSA and the effect of donor-recipient MHC non-identity between various cell populations (e.g. recipient T cell-donor LSEC).

Immunohistochemistry staining of "normal" livers (donors, incidental operative biopsies, etc.) shows strong, diffuse, ABO and class I MHC antigen expression on all cells, albeit the latter is weaker on hepatocytes (202-214) (Table 1). Liver MPS cells also show MHC class II staining, but weaker than similar cells within other organs (2, 12, 16), with DQ being weakest (202-215). Portal and central vein and hepatic artery endothelium is normally class II negative. Precise descriptions for PCP, lymphatic and inlet venule endothelia are lacking, but portal capillary endothelial class II expression appears weaker and patchier than renal peritubular (203, 216) or heart interstitial capillaries (203, 217). Possible explanations include class II downregulation by IL-10 and prostaglandins from endotoxin-stimulated Kupffer cells (2, 218, 219). Although PCP are fed by the systemic circulation, they are bathed in lymph fluid produced in the sinusoids. However, more work examining specific compartments is needed.

Inflammatory stimuli (esp. γ -interferon) heighten MHC class I expression and induce class II in endothelia, BEC, and hepatocytes (DR>DP>DQ) (202-215). Practical consequences include variable DSA targeting, immune stimulatory capability, and effector efficacy dependent on immune complex density (139, 220, 221) provoked by co-existent pathology (e.g. TCMR, HCV) (76, 199-201) providing the potential for improved outcome with target antigen modulation (222, 223).

Recipient bone marrow-derived hematolymphoid cells (e.g. lymphocytes, macrophages/Kupffer cells (224-229), and dendritic cells) replace the majority of donor equivalents within months after transplantation (210, 225, 226, 230). Yolk sac-derived KC replacement confounds steady state ontogenic classification (231)), but microenvironmental influences reprogram chromatin to largely match tissue-specific identities of the original embryo-seeded population (232). Whether allograft disease, immunological mismatch or immunosuppression affects that “naturalizing” process is unknown, but intuitive.

Stellate and myofibroblastic cells can arise from BM-derived precursors(233, 234) and might contribute up to ~12% of myofibroblasts in sex-mismatched liver allografts(235), but few studies critically address this question. Initial enthusiasm for reports of recipient-derived hepatocytes and BEC in allografts (236, 237) dwindled when subsequent data questioned its magnitude (229, 230, 238-240).

Most reports suggest no/sparse replacement of the donor endothelium (226, 228-230, 241, 242); the few that differed (237, 243) did not find a correlation with tolerance (243).

Hepatic stellate cells (HSC), portal fibroblast/myofibroblasts, and myeloid suppressor cells

HSCs (peri-sinusoidal cells, fat-storing cells, and lipocytes) comprise ~10% of all liver cells and are the major source of myofibroblasts and fibrosis(244-250). They reside in Disse’s space, throwing out long cytoplasmic extensions (~40 μ m)(251), and hold ~80% of Vitamin A and retinoid stores(252, 253). Depletion models (254) identify HSC as the main contributors to liver fibrosis (255, 256) (above portal fibroblasts and myeloid suppressor cells (257-259)) and so therapeutic approaches to arrest/reverse fibrosis target HSC(260-262).

Quiescent human HSC express vimentin and type III intermediate filament protein, suggesting a myogenic or fibroblastic origin (263). Quiescence is maintained in part by LSEC via VEGF-mediated nitric oxide (NO) production (264, 265). After liver injury or exposure to danger signals like endotoxin(266, 267), stellate cells activate, losing retinoid stores and trans-differentiating into proliferating, contractile myofibroblasts (α -smooth muscle actin (α -SMA)+) (244) that produce collagen, other ECM components and trophic factors (263, 268, 269).

HSC activate in two stages (246, 270). “Initiation” involves transdifferentiation, proliferation and migration to injury sites (271-275). “Perpetuation” involves autocrine and paracrine signals, the latter from damaged/apoptotic hepatocytes (including TGF- β 1 and ROS), activated KC, inflammatory cells and altered ECM composition(246, 270, 276-279). Activated HSCs elaborate inflammatory cytokines and chemokines (280-288). Examples that facilitate fibrosis include neutrophil recruitment (IL8), facilitating recruitment of CD8+ T cells to porto-septal areas (CCL2) in chronic viral hepatitis (280, 282, 289-293).

Inflammatory cell-derived IL-17A induces HSC collagen type I expression directly and indirectly via TGF- β from KC (294). Together, these damage signals promote a relative predominance of tissue inhibitors of MMP (TIMPs) over metalloproteinases (MMPs), which favors net ECM deposition (295). Activated HSC (SMA+) have been used to predict fibrosis development in HCV+ allografts(296). If the injury resolves, HSC can revert to quiescence or delete by apoptosis (297-307).

Activated state persistence results in fibrosis progression (26, 308). Nevertheless, when injury resolves, immunomodulation by HSC can instead limit fibrogenesis(309) via: a) anti-inflammatory mediators such as IL-10 (287, 288); b)

expansion of FoxP3⁺ regulatory T cells; c) apoptosis of CD4⁺ and CD8⁺ T cells in fibrosis areas (287, 310); and d) stimulation of hepatocyte NO synthesis (285, 311), which together lead to T cell suppression (312, 313).

Portal fibroblasts (PFbs): In contrast to HSC, PFbs (314), lack vitamin A autofluorescence, GFAP, NGFRp75 and synaptophysin expression (244, 314), but early after bile duct ligation/cholestatic injury (257), or isolation (315) activate and differentiate into myofibroblasts expressing α -SMA, fibulin-2, elastin, NTPDase2, Thy1 (314, 316-318) and ECM including collagen type I. PFbs likely contribute to non-biliary fibrogenesis (e.g. viral hepatitis, alcohol) (318), but much remains speculative because of difficulty to unambiguously discriminate them from activated HSCs (257-259).

Myeloid-derived suppressor cells (MDSC) are a heterogeneous bone marrow-derived population (319) identified in humans as CD11b⁺ CD33⁺MHC-DR^{low} cells(320). MDSC are induced by an inflammatory microenvironment (e.g. viral hepatitis (321-323)) and mediators (324, 325), or from peripheral blood mononuclear cells (PBMCs) by HSC (326). They potently suppress T cell function (327), while immunoregulatory functions likely affect fibrogenesis (255) including HSC fibrogenesis via IL-10 secretion (328), although probably with redundancy of effect (329).

THE MONONUCLEAR PHAGOCYTE SYSTEM (MPS)

Three nominal cell types comprise the human hepatic MPS: DC, monocytes and macrophages- resident and acquired (Figure 4). Innate and adaptive immune functions assisted by resident MPS cells are comprehensive, affecting hepatic responsiveness to immunological, toxicological, metabolic or preservation/reperfusion challenges and regeneration, fibrogenesis and fibrosis resolution (reviewed in (19, 330-332)). Macrophage reactions are conditioned by their tissue environment and they are often among initial responders to disease. Their broad response repertoire invites therapeutic targeting. Although broadly comparable among species, MPS cells also show significant genetic regulation, phenotype, and prevalence differences (333-338).

Resident macrophages are sculpted by tissue specialization: transcriptomic/marker diversity among resident macrophages from different tissues exceeds their divergence from other myeloid cell types (339, 340). Nevertheless, different resident macrophages and monocyte-derived macrophages share steady state transcriptional signatures largely related to phagocytosis (337, 339). Steady state liver resident KC and monocytes function as independent mature lineages (341), but in disease, phenotypic boundaries become blurred (342-344).

Dendritic Cells (DC) and other non-professional APC

Classical/myeloid and plasmacytoid DC, evolve from a common bone marrow-derived DC precursor independent of monocytes and depend on FMS-like tyrosine kinase 3 ligand (FLT3L) for local hepatic expansion (231, 345-347). KC steadily recruit circulating recipient DC precursors in the sinusoids, which migrate into Disse's space (348), and enter portal-based terminal lymphatic capillaries, followed by drainage to regional nodes (171, 349-351) (Figure 4).

Most DC reside in portal tracts and around central veins (197, 211, 352), perhaps related to pre-lymphatic collagen fiber tracts(171, 188-190, 192, 194).

Normal liver DC have low co-stimulator expression (347, 353, 354) and readily produce IL-10 after TLR4 ligation - a tolerogenic state encouraged by abundant tissue IL-10 and TGF β and by direct contact with adjacent sinusoidal endothelium (355).

Donor DC remain capable of triggering immunogenic responses critical to TCMR, albeit less efficiently than lymphoid tissue-based DC (4, 347, 353, 356-359). Recipient T cells directly recognize allogeneic MHC on donor DC that migrate to recipient central lymphoid tissues (197, 360) and residual donor DC within the allograft (197). Mass donor DC and other leukocyte migration early after transplantation contributes to activation-induced deletion (361-365). Their long-term persistence might contribute to tolerance maintenance (366, 367). Recipient DC uptake alloantigen and indirectly present or acquire whole non-self MHC from donor DC by trogocytosis or exosome uptake and present it semi-directly (368, 369).

Plasmacytoid DC regulate NK cells and are usually tolerogenic (influenced by the gut microbiome (370)), but can activate CD4 T cells when strong innate activation signals are present. Plasmacytoid DC and mature CD14^{dim} sentinel monocytes rove within sinusoids patrolling for virus. They react to engulfed or cytosolic virus sensed via TLR7 or TLR9 by secreting type I interferons (358) and accumulate in sinusoids during viral and non-viral liver disease (371-373). pDC may also be responsible for cytokine storm syndromes driven by viral activation of TLR (374).

“Non-professional” APC include LSEC, BEC, hepatocytes, KC, HSC, and MDSC (3). KC cross-present antigen captured from other cells (375), while MHC/MHC molecule transfer between different cells through trogocytosis or exosomes (MHC dressing) potentially enables a variety of unconventional antigen-specific activation or suppression of T cells in disease (368, 369). Interactions between non-professional APC and naïve CD8 T cells usually fosters tolerance due to low co-stimulation and inflammatory signaling needed for priming (reviewed by (376)), such that liver-activated CD8 T cells can be rapidly cleared by suicidal emperipolesis within hepatocytes (377) or by apoptosis (378).

However, liver macrophages can activate naïve CD4 T cells to sustain local functional CD8 T cell generation (379). Some monocyte-derived cells transmigrating from sinusoids, particularly post-phagocytic, acquire an immune regulatory transcriptome and phenotype resembling DC (“monocyte-derived DC” or “antigen-presenting macrophages”) (380-383); differences from classical DC are not clearly defined (195, 231, 384).

Kupffer Cells (KC)

KC, ~15% of all liver cells, are relatively long-lived, resident, sinusoidal-based, tissue macrophages with 2-3 fold periportal predominance, where they tend to be larger and more phagocytic (385-387). Most KC in resting livers lie between or cling over LSEC (Figure 4) with anchors through larger fenestra, have a ruffled surface with processes extending to sample slow flowing sinusoidal blood (388) and derive from extra-embryonic yolk sac hematopoietic precursors (389, 390), whose progeny migrate to the liver and accommodate with local microenvironmental signals (232, 391). Short term, KC are stellate and immobile (392), but they redistribute over weeks to form granulomas after insults, with their sinusoidal place supplanted by recruited monocyte-derived cells (393). In the steady postnatal state mature rodents and perhaps human KC renew themselves as necessary (enhanced with IL4 (343, 394)) without requirement of other input sources such as bone marrow-derived

monocytes (395-400). KC, however, are replaced within months after transplantation (210, 225, 226, 230).

Hepatic microenvironmental signals determine the homeostatic set points and the KC response spectrum but they excel at capture and clearance, including: circulating particles (>230 nm (174, 344, 401, 402)), circulating bacteria (392, 393), and oxidatively damaged red cells and haptoglobin-haemoglobin complexes, expedited by scavenger receptors (403, 404). Opsonized particles and pathogens and immune complexes(405) are recognized via Fc and complement C3 receptors – primarily CRIg (406). KC manage steady state antigenic particle phagocytosis with tolerance: patrolling antigen-specific regulatory CD4 T cells arrest on KC and are activated (but CD8 T cells are not), inducing a KC-dependent systemic tolerance (344).

Bacteremia is cleared by direct engulfment or trapping and interaction with other innate defenses, such as platelets to encase the bacteria (407), or neutrophils, for which the KC surface becomes a platform to kill bacteria. Subsequent clearance of apoptotic neutrophils by KC may return it to the native tolerogenic state (408-410). After extensive phagocytosis, macrophages/KC may migrate to portal tracts (411).

Relative hepatic resistance to AMR is an incidental byproduct of vigorous KC clearance of alloantibody complexed with soluble MHC class I, along with activated complement and platelets (22); KC depletion reverses this resistance(20, 21, 412, 413).

Identification: KC are difficult to isolate from liver in a representative way (339, 414), rapidly alter phenotype upon extraction (415), display a liver microenvironment epigenetic dependence and are less well-studied than other tissue macrophages (343, 393). Although difficult to sensitively discriminate on routine histology (416), KC appearance yields clinically relevant clues: hypertrophy and ceroid-loading (suggests recent cell debris phagocytosis and marks injury sites (416)); phagocytosed bile or foamy macrophages (indicate cholestasis); iron accumulation; erythrophagocytosis; fusion; topographic association with specific inflammatory cells (e.g. eosinophilic microvasculitis in AMR).

There is no KC-specific immunophenotypic marker, but useful practical markers in formalin-fixed biopsies combined with morphological assessment include CD68 (417-421), CD163 (404, 417, 422, 423)) and 25-F9 (424, 425). CD68 also marks plasmacytoid DC, while CD68, CD163 and other general resting macrophage markers such as CD64 and MERTK are expressed on some monocytes/monocyte-derived cells (339, 426-431). KC immunophenotype is described for various immune markers in clinical biopsies of normal liver, back table biopsies or stable grafts (424, 425, 432-439) but discrimination from infiltrating monocyte-derived cells in disease settings is not always possible.

Proteomic-transcriptomic screening identify highly expressed immunohistochemical signatures of resting and stimulated macrophages: phagocytosis, redox control, adhesion, fibrinolysis, lipid metabolism, etc. (440). Some markers are pleiotropic (e.g. Galectin-3) or not macrophage-restricted (e.g. transglutaminase 2 and galectin-3: hepatocytes; CD206: sinusoidal endothelium), necessitating multiplex staining for macrophage-specific evaluation.

Monocyte-derived cells in the steady state: Circulating monocytes do not reflect those sequestered by the hepatic microcirculation (441, 442). Human and murine monocytes show broadly comparable maturing populations, but different proportions

and gene expression patterns (430, 442). In the steady state, predominantly immature CD14+ (“classical”) circulating monocytes arrest and transmigrate into Disse’s space, acquiring increased MHCII; the majority patrol extravascular tissue as phagocytes with an anti-inflammatory tolerogenic phenotype (reduced response to LPS; suppressive of T cell activation) (443). Most such transmigrated monocytes probably traffic to afferent portal tract lymphatics and on to regional lymph nodes (427). Less mature monocytes (CD14+) may pass through the sinusoids and exit in hepatic venous blood, or may arrest and transmigrate past sinusoidal endothelium (dependent on VAP-1, CX3CL1 and VCAM-1(444)). A minority reverse transmigrate back into the sinusoid, acquiring CD16, increased scavenger receptors (CD163 and CD206) and a pro-inflammatory immune-activating capacity to secrete γ -IFN and induce effector T cells (443).

Thus the sinusoidal endothelium fosters both recruitment and then functional and anatomic partitioning of monocytes into pro- and anti-inflammatory phenotypes. CD16_{high} (“non-classical”) intravascular monocytes are small motile cells that patrol endothelium for virus, sensed by TLR7 or TLR8 (445), analogous to murine sentinel microvascular monocytes (441) that perform low-grade endothelial particle scavenging (397, 441, 446) without differentiating to macrophages (339, 427). Tissue nucleic acid sensing via TLR7 elicits a mixed luminal capillaritis: monocytes cluster and engage neutrophils to kill adjacent endothelium, removing injured or infected cells (446). The fate of such CD16_{high} intra-sinusoidal pro-inflammatory monocyte-derived cells is not clear, but may include further transmigration and lymphatic egress (447).

In normal liver and stable liver allografts, portal macrophages are scarce, except for occasional ceroid-laden post-phagocytic cells (448).

Monocyte reactions: MPS cells accumulate during liver inflammation (including TCMR) due to enhanced sinusoidal recruitment of circulating intermediate CD16+ monocytes, mediated by constitutive and induced ligands (224, 444). In fibrosis, leukocytes can also exit portal and septal venules (449, 450). Monocytes transmigrate and differentiate into proliferating macrophage infiltrates heterogeneous for various antigen presentation, cytokine secretion and phagocytosis activities (343, 381, 393, 436, 451-454). In acute TCMR activated macrophages accumulate in portal tracts (438), although perivenular, veno-occlusive and lobular hepatitic patterns of active TCMR exist (224, 437, 455-461). Indeed, KC hypertrophy and lobular macrophage infiltrates occur in TCMR, chronic rejection (437, 448, 462) and AMR (463-465). Inflammatory macrophages further contribute to chronic rejection by causing apoptosis of bile duct epithelium and hepatocytes via CD40-dependent mechanisms (437, 466). In severe TCMR, KC scavenge major basic protein (PRG2) from eosinophils (467), which are macrophage activators (468). TLR9-dependent reactions can augment viral immunity resulting in distinctive parenchymal monocyte-derived macrophage clusters that support effector CD8 T cell proliferation over several days with little hepatocellular injury (469).

Phenotypic macrophage diversity: The “immunologically activated macrophage” (470, 471) concept evolved from a non-specific microbiocidal state induced in antigen-dependent reactions to encompass “alternative activation” (e.g. helminth infection) and dichotomous polarization (M1 or M2 states; later with subtypes) based on culture changes after isolated stimuli. The linear model was revised to an activation spectrum (472, 473): helpful to explore macrophage activities in culture,

but labels do not capture individual macrophage behaviors in tissue pathology (342, 472, 474).

Macrophages show transcriptional shifts as tissue responses wax and wane (338), and epigenomic memory affects subsequent responses on repeated stimulation(475). Transcriptomic analyses found 49 different gene co-expression clusters motivating a dozen or so inducible response states to soluble signals alone (476, 477). Stimuli segregated into those causing widespread or limited transcriptional changes from culture norms, but not along M1-M2 divisions (477). Genetic evidence also fails to identify distinct pre-committed macrophage subsets, although single cell-resolution studies in disease are lacking. Instead, transcriptomic, proteomic and multiplex marker data highlight process-orientated signatures that characterize maturational, and functional states (337, 340, 472, 478).

Inflammatory macrophage activation is coupled to obligate restraining tissue feedback systems involving macrophages themselves (intrinsic reprogramming), activated stellate cells, hepatocytes, mast cells and others (343, 454, 479-483). Inhibitory systems predominate when inciting stimuli diminish: incoming macrophages express increasing regulation (326), scavenging and repair signaling, and monocyte-derived macrophages and self-renewal replace depleted KC (343, 393, 454, 484).

“Activity” marker interpretation, therefore, requires context: MERTK is immunosuppressive, but tied to prior immune activation and TLR engagement which it attenuates safely (482). In this context, MERTK reflects immune activation, although by preventing endotoxic shock it is anti-inflammatory (485). Likewise, CD163+/HO-1+ haemophagocytes in macrophage activation syndromes and sepsis probably represent a compensatory anti-inflammatory response to excessive innate activation (374, 486-489). Therefore, characterization of ‘markers’ by downstream actions may not make sense if the upstream context and positioning of that response is ignored.

More complications arise when markers are pleiotropic (e.g. MERTK also promotes efferocytosis of dead cells by macrophages (490)). Such considerations might explain heterogeneity and “unorthodox” concurrence of culture-defined “macrophage polarity” markers in clinical disease infiltrates (342). More comprehensive multiplex profiling in diseased tissue sections might better reveal individual macrophage engagement (472).

TOLERANCE MECHANISMS

Through tolerance, potentially harmful responses to innocuous antigens from gut commensals or food are prevented, with incidental benefits for transplantation (5, 15), but also favoring HCV and HBV persistence resulting in fibrosis/cirrhosis (2, 491). The tolerogenic MPS phenotype includes moderate surface MHCII (424) with little co-stimulatory CD80/CD86 (438) and immunosuppressive factor expression including PDL-1 (344) and MERTK (482), combined with IL-10 and TGF β production(3, 5, 14, 15, 17, 32, 344). KC, DC, and LSEC numbers and immunoregulatory state are closely linked with the gut microbiome (11, 492, 493) and influenced by pattern recognition receptors (PRR) including NOD-like and Toll- like receptors (TLR2-4 and TLR9) (433, 492, 494). PRR report the stream of microbial-associated molecular patterns (MAMPs) in sinusoidal blood, such as endotoxin and flagellin (2, 495, 496). Depletion of lymphocyte substrates (e.g. arginase) and vasoactive molecule secretion (adenosine) promote tolerance as an ancillary benefit (Figure 5). Even during inflammation, factors such as contact with

activated stellate cells promote tolerance (326). Nevertheless, the resting state is not innocuous, as liver deprived of MAMP stimulation shows less reperfusion injury (496).

Recent reviews(2, 3, 5, 13-15, 361, 497-499) attribute “liver *allograft* tolerance” to: 1) donor hematopoietic properties, including: a) long-term microchimerism(225, 230, 366, 500); b) activation-induced deletion of recipient effector lymphocytes(361, 362); and c) deficient antigen presentation because of low-level MHC and co-stimulator and/or enhanced inhibitory molecule expression(501); 2) recipient lymphocyte activation by other “tolerogenic” APC (e.g. LSEC, KC, stellate cells, myeloid suppressor cells, hepatocytes) causing apoptosis of effector cells, anergy, exhaustion/senescence, and/or Treg generation (Figure 5); and 3) large antigen load including soluble donor MHC class I molecule secretion (2, 3, 5, 13-15, 361, 497-499). Indeed, chronic exposure (>5 years) to high antigen load appears to contribute to lymphocyte senescence and operational tolerance(502-504) and other complications in humans (505).

Early reviews considered potential contributions from donor-specific “enhancing” antibodies (506-508) - a concept largely abandoned in the antibody era of transplantation(509). Mechanistic theories for regulatory antibody roles include antigen reactive cell opsonization(ARCO)(506-508) and Fc binding and immune complex formation(510, 511). Indeed, Hepatology has mostly viewed antibodies as “biomarkers” but not relevant effectors – dismissing their pathogenic potential despite decades-old (21, 512) and recent evidence to the contrary in acute(513) and chronic settings(167, 514).

Operationally “tolerant” human liver allograft recipients often harbor circulating DSA (186, 515) and might not be considered “truly tolerant” by basic immunologists. However, overt tissue damage is not always observed in this setting(186), similar to “tolerant” rodent liver(506), “enhanced” rodent kidney allograft recipients, and enhanced tumor models (508). All show circulating class II DSA, but a histologically normal graft or non-rejected tumor (506-508). The failure to translate rodent enhancement protocols to patients has been attributed to lack of microvascular capillary class II expression in rodents, contrasted with its presence in humans (506-508). Whether DSA+ “tolerant” liver allograft recipients, who show low-level microvascular MHC class II expression, will eventually indolently manifest DSA-mediated injury and fibrosis in areas not accessible to biopsy or be able to withstand low-level injury because of “defense” mechanisms, described above, is uncertain.

Pathological stimuli that break tolerance include live microorganisms, increased endotoxin and endogenous damage-associated molecular patterns (DAMPs), such as high-mobility group box 1 (HMGB1) from hepatocytes after preservation-related injury, which is sensed by TLR4 (516-520). Such stimuli generate second signals (521) for antigen presentation and T cell activation by KC (increasing CD80 and decreasing PDL-1) (344, 522) and upregulating MHC class II antigens on the microvasculature, perhaps facilitating DSA tissue recognition (76, 199). Interestingly, the presence or absence of an effector response in allogeneic tumor enhancement models has been attributed to the amount of tissue complement activation (523). CIITA-induced class II upregulation can also boost tumor recognition(524). These observations highlight the consilience between immune checkpoint regulation in tumor and transplantation immunology(62): the former attempts to activate T cells and/or block inhibitory signaling in contrast to the latter.

Loss of local and systemic Kupffer-dependent tolerance to antigenic particles activate immune responses (344). KC are also capable activators of patrolling

invariant sinusoidal NKT cells (iNKT), by presenting microbial lipid antigens with MHC-I-like molecule CD1d (392). The activated iNKT cells arrest, cluster on the KC and produce IFN- γ (392, 525). By releasing CXCL16, KC and monocyte-derived macrophages recruit NKT cells after acute liver injury, which increases monocyte infiltration and fibrogenesis (526). Nevertheless, liver allograft target antigen modulation is a reasonable approach to treatment of chronic AMR.

SUMMARY AND FUTURE DIRECTIONS

The principle of “form follows function” originally coined by American architect, Louis Sullivan, holds true for hepatic immune anatomy. The positioning and microcirculatory design expedite interaction: a) with the external environment delivered via the gut/splanchnic circulation; and b) between innate and adaptive immunity. Byproducts are then exported via the lymphatics or bile. Cellular interactions and outcome have been extensively studied and cells cast as primary agents of liver injury. Antibodies are relegated to a biomarker-only role, signaling systemic immune activation, but recent evidence argues against this viewpoint, at least in allograft livers.

Specific molecular pathways discussed above have been associated with hepatic-based tolerogenic T cell signaling in non-transplant settings and validly projected on to an understanding of “hepatic allograft tolerogenicity”. However, a knowledge gap is shown by inability to reliably translate these principles to patients. Instead, an accelerating phase of observational/discovery science has come to rely increasingly on large data sets and cross-platform analyses. This gap might be minimized by applying lessons learned in tumor immunology, which mirror images transplantation immunology.

Insufficient attention to basic biology and hypothesis-testing science and becoming mired in ever increasing detail without a “systems” understanding will likely slow further development. For example, decades-old knowledge that anti-donor antibodies are present in “tolerant” rodent liver allograft recipients led to an incomplete understanding and search for biomarkers in “tolerant” human liver allograft recipients. Therefore, a better understanding of MPS biology, parallels between cancer and transplantation immunology, MHC class II antigen regulation and their relationship to qualitative and quantitative composition of gut microbiome, gut-derived hormones, diet, and medications should receive increasing attention.

Thus, liver allograft immunology will assuredly embrace “discovery science” platforms, but integrate findings into structural-functional relationships.

Figure 1. Hepatic Artery and Biliary Tree

(A) Gross view of the “tolerogenic” hepatic parenchyma enveloping the centrally- placed biliary tree, which are usefully conceptualized as 2 interdependent organs. The common hepatic duct (blue) bifurcates to hepatic ducts (yellow), which branch to segmental (red; 0.4-0.8 mm) then area ducts with their branches (green; 0.3-0.4 mm). These first generation branches are macroscopically visible “large intrahepatic bile ducts”. A further 7-8 branchings generate septal (>0.1 mm) and interlobular ducts, culminating at ductules and canals of Hering. (B) Extra-hepatic and large intra-hepatic bile ducts contain rows of anastomosing peri-biliary glands that produce mucous and serous secretions. (C) Cross-section of a large intra-hepatic portal tract showing afferent layer of the peri-biliary capillary plexus (PCP; IPEX: brown) that lies immediately beneath the single layer of BEC (IPEX stain for AE1/3: red), shown at higher magnification in the lower right inset. (D) High power magnification of actual terminal portal tract: note the continued close association between capillaries (brown) and the BEC (red).

Figure 2. Microvascular lobular architecture

A 3-dimensional (3D) idealized view of a **classic hepatic lobule** (right panel) is formed by **terminal portal tracts (PT)** at the vertices of a roughly hexagonal structure, which notionally carry PV parenchymal and HA branches, BD, nerves and lymph channels surrounded by fibrosis tissue (left upper and middle panels (1)). This anatomic design contributes to histologic patterns in vascular disease and functional hepatocyte specialization zones (A: periportal; B: midzonal; and C: perivenular or centrilobular). The figure omits some elements of curvature and variations around large conducting portal vein branches for simplicity.

Figure 3. Hepatic Arterial Buffer Response

The hepatic arterial buffer response (HABR) (58, 59). Increased (portal hyperperfusion in reduced-size livers or after partial hepatectomy) or decreased portal venous flow (sclerosis, thrombosis), reciprocally regulates arterial resistance/vasospasm and flow primarily via adenosine, but other mediators are also likely involved (58, 60, 61).

Figure 4. Hepatic MPS System and hepatic sinusoid structure

Recipient leukocytes from arterial and portal venous blood and pass from portal tracts into sinusoid lumens dressed with relatively static resident macrophages - KC. Slow flowing blood in the highly branched sinusoids is extensively sampled by KC for particulate matter (damaged red cells, immune complexes, opsonized particles), live organisms and soluble signals such as MAMPS from the gut microbiome. KC

defenses to blood-borne infection are heavily integrated with other innate systems including platelets and granulocytes.

Traffic patterns of immature classical/myeloid and plasmacytoid DC and monocytes (see text for details). In steady state, most transmigrated monocytes develop a tolerogenic phagocytic phenotype and traffic along Disse's space to portal tract lymphatics. Some transmigrated monocytes reverse-migrate back into sinusoids (becoming CD16+) as motile cells with pro-inflammatory immune activating and sentinel functions. Monocyte-derived cells can transport antigen to lymphatics, differentiate to tissue macrophages or to monocyte-derived DC. This supply system becomes massively upregulated after liver injury or infection to generate inflammatory infiltrates, including rejection and specialized inflammatory structures such as granulomas and intrahepatic myeloid cell aggregates for T cell population expansion (iMATEs).

Figure 5. Hepatic Tolerance Mechanisms

Hepatic immune reactivity accommodates the rich stream of mostly innocuous portal venous blood with food and microbial antigens, while retaining sensitivity to genuine danger signals from live organisms and/or tissue damage. Efficient circulating particle clearance is led by Kupffer cells; scavenging is combined with immune sensor functions in Kupffer, dendritic and LSEC. Cell responses show a predisposition to tolerance mediated by a self-regulating network of cell intrinsic (epigenetic), soluble microenvironmental (TGF β , IL-10) and cell surface states (relatively low MHCII and co-stimulators, negative immune regulators such as PDL-1), as discussed in the text.

Abbreviations: PDL-1, programmed death ligand-1; T_{reg}, regulatory T cell; NKT cell, natural killer T cell; PDC, plasmacytoid dendritic cell; LSECtin, liver and lymph node sinusoidal endothelial C-type lectin; CD95L, CD95 ligand; PGE₂, prostaglandin E₂; TGF β , transforming growth factor β ; L, lymphatic; TNF, tumor necrosis factor; ROS, reactive oxygen species.

REFERENCES

1. Böttcher JP, Knolle PA, Stabenow D. Mechanisms balancing tolerance and immunity in the liver. *Dig Dis* 2011;29(4):384-390.
2. Thomson AW, Knolle PA. Antigen-presenting cell function in the tolerogenic liver environment. *Nat Rev Immunol* 2010;10(11):753-766.
3. Crispe IN. Immune tolerance in liver disease. *Hepatology* 2014;60(6):2109-2117.
4. Thomson AW, Geller DA, Gandhi C, Murase N, Demetris AJ, Beer-Stolz D. Hepatic antigen-presenting cells and regulation of liver transplant outcome. *Immunol Res* 2011;50(2-3):221-227.
5. Jenne CN, Kubes P. Immune surveillance by the liver. *Nat Immunol* 2013;14(10):996-1006.
6. Fung J. Management of chronic hepatitis B before and after liver transplantation. *World J Hepatol* 2015;7(10):1421-1426.
7. Ghaziani T, Sendi H, Shahraz S, Zamor P, Bonkovsky HL. Hepatitis B and liver transplantation: molecular and clinical features that influence recurrence and outcome. *World J Gastroenterol* 2014;20(39):14142-14155.
8. Muir AJ, Naggie S. HCV treatment: is it possible to cure all HCV patients? *Clin Gastroenterol Hepatol* 2015.
9. Pipili C, Cholongitas E. Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand? *World J Hepatol* 2015;7(12):1606-1616.
10. Demetris AJ, Isse K. Tissue biopsy monitoring of operational tolerance in liver allograft recipients. *Curr Opin Organ Transplant* 2013;18(3):345-353.
11. Bogdanos DP, Gao B, Gershwin ME. Liver immunology. *Compr Physiol* 2013;3(2):567-598.
12. Knolle PA, Gerken G. Local control of the immune response in the liver. *Immunol Rev* 2000;174:21-34.
13. Sánchez-Fueyo A, Strom TB. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. *Gastroenterology* 2011;140(1):51-64.
14. Karimi MH, Geramizadeh B, Malek-Hosseini SA. Tolerance Induction in Liver. *Int J Organ Transplant Med* 2015;6(2):45-54.
15. Adams DH, Sanchez-Fueyo A, Samuel D. From immunosuppression to tolerance. *J Hepatol* 2015;62(1S):S170-S185.
16. Knolle PA, Löser E, Protzer U, Duchmann R, Schmitt E, zum Büschenfelde KH et al. Regulation of endotoxin-induced IL-6 production in liver sinusoidal endothelial cells and Kupffer cells by IL-10. *Clin Exp Immunol* 1997;107(3):555-561.
17. Knolle PA, Thimme R. Hepatic immune regulation and its involvement in viral hepatitis infection. *Gastroenterology* 2014;146(5):1193-1207.
18. Ogawa H, Rafiee P, Heidemann J, Fisher PJ, Johnson NA, Otterson MF et al. Mechanisms of endotoxin tolerance in human intestinal microvascular endothelial cells. *J Immunol* 2003;170(12):5956-5964.
19. Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE. Kupffer cells in the liver. *Compr Physiol* 2013;3(2):785-797.
20. Gugenheim J, Charpentier B, Gigou M, Cuomo O, Calise F, Amorosa L et al. Delayed rejection of heart allografts after extracorporeal donor-specific liver hemoperfusion. Role of Kupffer cells. *Transplantation* 1988;45(3):628-632.
21. Demetris AJ, Murase N, Nakamura K, Iwaki Y, Yagihashi A, Valdivia L et al. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. [Review]. *Seminars in Liver Disease* 1992;12(1):51-59.
22. Nakamura K, Murase N, Becich MJ, Furuya T, Todo S, Fung JJ et al. Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. *American Journal of Pathology* 1993;142(5):1383-1391.

23. DeLeve LD. Liver sinusoidal endothelial cells and liver regeneration. *J Clin Invest* 2013;123(5):1861-1866.
24. Michalopoulos GK. Principles of liver regeneration and growth homeostasis. *Compr Physiol* 2013;3(1):485-513.
25. Ding BS, Cao Z, Lis R, Nolan DJ, Guo P, Simons M et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. *Nature* 2014;505(7481):97-102.
26. DeLeve LD. Liver sinusoidal endothelial cells in hepatic fibrosis. *Hepatology* 2015;61(5):1740-1746.
27. Okazaki I, Maruyama K. Collagenase activity in experimental hepatic fibrosis. *Nature* 1974;252(5478):49-50.
28. Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. *Gut* 2015;64(5):830-841.
29. Ramachandran P, Iredale JP, Fallowfield JA. Resolution of liver fibrosis: basic mechanisms and clinical relevance. *Semin Liver Dis* 2015;35(2):119-131.
30. Demetris AJ, Ruppert K, Dvorchik I, Jain A, Minervini M, Nalesnik MA et al. Real-time monitoring of acute liver-allograft rejection using the Banff schema. *Transplantation* 2002;74(9):1290-1296.
31. Doherty DG, O'Farrelly C. Innate and adaptive lymphoid cells in the human liver. *Immunol Rev* 2000;174:5-20.
32. Doherty DG. Immunity, tolerance and autoimmunity in the liver: A comprehensive review. *J Autoimmun* 2015.
33. Sakamoto T, Ye Q, Lu L, Demetris AJ, Starzl TE, Murase N. Donor hematopoietic progenitor cells in nonmyeloablated rat recipients of allogeneic bone marrow and liver grafts. *Transplantation* 1999;67(6):833-840.
34. Sakamoto T, Murase N, Ye Q, Starzl TE, Demetris AJ. Identification of donor hematopoietic progenitor cells after allogeneic liver transplantation. *Transplant Proc* 1997;29(1-2):1211.
35. Chen WJ, Ying DJ, Liu ZJ, He ZP. Analysis of the arterial supply of the extrahepatic bile ducts and its clinical significance. *Clin Anat* 1999;12(4):245-249.
36. Sakai T, Hosoyamada Y. Are the precapillary sphincters and metarterioles universal components of the microcirculation? An historical review. *J Physiol Sci* 2013;63(5):319-331.
37. Oda M, Yokomori H, Han JY. Regulatory mechanisms of hepatic microcirculatory hemodynamics: hepatic arterial system. *Clin Hemorheol Microcirc* 2006;34(1-2):11-26.
38. Takasaki S, Hano H. Three-dimensional observations of the human hepatic artery (Arterial system in the liver). *J Hepatol* 2001;34(3):455-466.
39. Takemura M, Oguma S, Mori S, Ishii M, Starzl TE, Demetris AJ et al. Peribiliary vascular diseases in rejected livers; computer-aided three-dimensional reconstruction and morphometry. *Transplantation Proceedings* 1991;23(1 Pt 2):1409-1412.
40. Kan Z, Madoff DC. Liver anatomy: microcirculation of the liver. *Semin Intervent Radiol* 2008;25(2):77-85.
41. Ekataksin W. The isolated artery: an intrahepatic arterial pathway that can bypass the lobular parenchyma in mammalian livers. *Hepatology* 2000;31(2):269-279.
42. Nakanuma Y, Hoso M, Sanzen T, Sasaki M. Microstructure and development of the normal and pathologic biliary tract in humans, including blood supply. *Microsc Res Tech* 1997;38(6):552-570.
43. Kobayashi S, Nakanuma Y, Matsui O. Intrahepatic peribiliary vascular plexus in various hepatobiliary diseases: a histological survey. *Hum Pathol* 1994;25(9):940-946.
44. Matsunaga Y, Terada T. Peribiliary capillary plexus around interlobular bile ducts in various chronic liver diseases: An immunohistochemical and morphometric study. *Pathol Int* 1999;49(10):869-873.
45. Demetris AJ. Ischemic cholangitis. *Mayo Clin Proc* 1992;67(6):601-602.
46. Ludwig J, Batts KP, MacCarty RL. Ischemic cholangitis in hepatic allografts [see comments]. *Mayo Clinic Proceedings* 1992;67(6):519-526.

47. Batts KP. Ischemic cholangitis. *Mayo Clin Proc* 1998;73(4):380-385.
48. Weeder PD, van Rijn R, Porte RJ. Machine perfusion in liver transplantation as a tool to prevent non-anastomotic biliary strictures: Rationale, current evidence and future directions. *J Hepatol* 2015;63(1):265-275.
49. Cardinale V, Wang Y, Carpino G, Mendel G, Alpini G, Gaudio E et al. The biliary tree--a reservoir of multipotent stem cells. *Nat Rev Gastroenterol Hepatol* 2012;9(4):231-240.
50. Op den Dries S, Westerkamp AC, Karimian N, Gouw AS, Bruinsma BG, Markmann JF et al. Injury to peribiliary glands and vascular plexus before liver transplantation predicts formation of non-anastomotic biliary strictures. *J Hepatol* 2014;60(6):1172-1179.
51. Oguma S, Belle S, Starzl TE, Demetris AJ. A histometric analysis of chronically rejected human liver allografts: insights into the mechanisms of bile duct loss: direct immunologic and ischemic factors. *Hepatology* 1989;9(2):204-209.
52. Matsumoto Y, McCaughan GW, Painter DM, Bishop GA. Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection. *Transplantation* 1993;56(1):69-75.
53. Escaned J, Flores A, Garcia-Pavia P, Segovia J, Jimenez J, Aragoncillo P et al. Assessment of microcirculatory remodeling with intracoronary flow velocity and pressure measurements: validation with endomyocardial sampling in cardiac allografts. *Circulation* 2009;120(16):1561-1568.
54. Shimizu A, Yamada K, Sachs DH, Colvin RB. Persistent rejection of peritubular capillaries and tubules is associated with progressive interstitial fibrosis. *Kidney International* 2002;61(5):1867-1879.
55. Adair A, Mitchell DR, Kipari T, Qi F, Bellamy CO, Robertson F et al. Peritubular capillary rarefaction and lymphangiogenesis in chronic allograft failure. *Transplantation* 2007;83(12):1542-1550.
56. Mills SJ, Cowin AJ, Kaur P. Pericytes, mesenchymal stem cells and the wound healing process. *Cells* 2013;2(3):621-634.
57. Armulik A, Genové G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. *Dev Cell* 2011;21(2):193-215.
58. Eipel C, Abshagen K, Vollmar B. Regulation of hepatic blood flow: the hepatic arterial buffer response revisited. *World J Gastroenterol* 2010;16(48):6046-6057.
59. Lautt WW. Mechanism and role of intrinsic regulation of hepatic arterial blood flow: hepatic arterial buffer response. *Am J Physiol* 1985;249(5 Pt 1):G549-556.
60. Kelly DM, Zhu X, Shiba H, Irefin S, Trenti L, Cocieru A et al. Adenosine restores the hepatic artery buffer response and improves survival in a porcine model of small-for-size syndrome. *Liver Transpl* 2009;15(11):1448-1457.
61. Demetris AJ, Kelly DM, Eghtesad B, Fontes P, Wallis Marsh J, Tom K et al. Pathophysiologic Observations and Histopathologic Recognition of the Portal Hyperperfusion or Small-for-Size Syndrome. *Am J Surg Pathol* 2006;30(8):986-993.
62. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* 2012;12(4):252-264.
63. Hartleb M, Gutkowski K, Milkiewicz P. Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension. *World J Gastroenterol* 2011;17(11):1400-1409.
64. Nakanuma Y, Katayanagi K, Terada T, Saito K. Intrahepatic peribiliary glands of humans. I. Anatomy, development and presumed functions. *J Gastroenterol Hepatol* 1994;9(1):75-79.
65. Tabibian JH, Masyuk AI, Masyuk TV, O'Hara SP, LaRusso NF. Physiology of cholangiocytes. *Compr Physiol* 2013;3(1):541-565.
66. Farina A, Delhay M, Lescuyer P, Dumonceau JM. Bile proteome in health and disease. *Compr Physiol* 2014;4(1):91-108.
67. Farina A, Dumonceau JM, Lescuyer P. Proteomic analysis of human bile and potential applications for cancer diagnosis. *Expert Rev Proteomics* 2009;6(3):285-301.

68. Beuers U, Hohenester S, de Buy Wenniger LJ, Kremer AE, Jansen PL, Elferink RP. The biliary HCO₃(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. *Hepatology* 2010;52(4):1489-1496.
69. Mizuguchi Y, S. S, Isse K, Lunz J, Demetris A. Biliary Epithelial Cells. In: Monga SPS, (ed). *Molecular Pathology of Liver Diseases*. 1st Edition ed. New York, NY: Springer, 2011: 27-52.
70. Demetris AJ. Immunopathology of the Human Biliary Tree. In: Sirica AE, Longnecker DS, (eds). *Biliary and Pancreatic Ductal Epithelia. Pathobiology and Pathophysiology*. New York: Marcel Dekker, Inc, 1997: 127-180.
71. Harada K, Nakanuma Y. Innate immunity in the pathogenesis of cholangiopathy: a recent update. *Inflamm Allergy Drug Targets* 2012;11(6):478-483.
72. Karimian N, Westerkamp AC, Porte RJ. Biliary complications after orthotopic liver transplantation. *Curr Opin Organ Transplant* 2014;19(3):209-216.
73. Ghobrial RM, Busuttil RW. Challenges of adult living-donor liver transplantation. *J Hepatobiliary Pancreat Surg* 2006;13(2):139-145.
74. Akamatsu N, Sugawara Y, Hashimoto D. Biliary reconstruction, its complications and management of biliary complications after adult liver transplantation: a systematic review of the incidence, risk factors and outcome. *Transplant international : official journal of the European Society for Organ Transplantation* 2011;24(4):379-392.
75. Buis CI, Hoekstra H, Verdonk RC, Porte RJ. Causes and consequences of ischemic-type biliary lesions after liver transplantation. *J Hepatobiliary Pancreat Surg* 2006;13(6):517-524.
76. Demetris AJ, Zeevi A, O'Leary JG. ABO-compatible liver allograft antibody-mediated rejection: an update. *Curr Opin Organ Transplant* 2015;20(3):314-324.
77. Salah A, Fujimoto M, Yoshizawa A, Yurugi K, Miyagawa-Hayashino A, Sumiyoshi S et al. Application of complement component 4d immunohistochemistry to ABO-compatible and ABO-incompatible liver transplantation. *Liver Transpl* 2014;20(2):200-209.
78. Song GW, Lee SG, Hwang S, Kim KH, Ahn CS, Moon DB et al. Biliary stricture is the only concern in ABO-incompatible adult living donor liver transplantation in the rituximab era. *J Hepatol* 2014;61(3):575-582.
79. Strazzabosco M, Fabris L. Development of the bile ducts: essentials for the clinical hepatologist. *J Hepatol* 2012;56(5):1159-1170.
80. Zong Y, Stanger BZ. Molecular mechanisms of bile duct development. *Int J Biochem Cell Biol* 2011;43(2):257-264.
81. Isse K, Lesniak A, Grama K, Maier J, Specht S, Castillo-Rama M et al. Preexisting epithelial diversity in normal human livers: a tissue-tethered cytometric analysis in portal/periportal epithelial cells. *Hepatology* 2013;57(4):1632-1643.
82. Limaye PB, Alarcon G, Walls AL, Nalesnik MA, Michalopoulos GK, Demetris AJ et al. Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development. *Laboratory investigation; a journal of technical methods and pathology* 2008;88(8):865-872.
83. Carpino G, Cardinale V, Onori P, Franchitto A, Berloco PB, Rossi M et al. Biliary tree stem/progenitor cells in glands of extrahepatic and intrahepatic bile ducts: an anatomical in situ study yielding evidence of maturational lineages. *J Anat* 2012;220(2):186-199.
84. Nakanuma Y, Sasaki M, Terada T, Harada K. Intrahepatic peribiliary glands of humans. II. Pathological spectrum. *J Gastroenterol Hepatol* 1994;9(1):80-86.
85. Nakanuma Y, Sasaki M. Expression of blood group-related antigens in the intrahepatic biliary tree and hepatocytes in normal livers and various hepatobiliary diseases. *Hepatology* 1989;10(2):174-178.
86. Phalipon A, Cardona A, Kraehenbuhl JP, Edelman L, Sansonetti PJ, Corthesy B. Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo. *Immunity* 2002;17(1):107-115.

87. Delacroix DL, Courtoy PJ, Rahier J, Reynaert M, Vaerman JP, Dive C. Localization and serum concentration of secretory component during massive necrosis of human liver. *Gastroenterology* 1984;86(3):521-531.
88. Daniels CK, Schmucker DL. Secretory component-dependent binding of immunoglobulin A in the rat, monkey and human: a comparison of intestine and liver. *Hepatology* 1987;7(3):517-521.
89. Nagura H, Smith PD, Nakane PK, Brown WR. IGA in human bile and liver. *J Immunol* 1981;126(2):587-595.
90. Manning RJ, Walker PG, Carter L, Barrington PJ, Jackson GD. Studies on the origins of biliary immunoglobulins in rats. *Gastroenterology* 1984;87(1):173-179.
91. Jackson GD, Walker PG. The transient appearance of IgM antibodies in the bile of rats injected with *Salmonella enteritidis*. *Immunol Lett* 1983;7(1):41-45.
92. Aagaard BD, Heyworth MF, Oesterle AL, Jones AL, Way LW. Intestinal immunisation with *Escherichia coli* protects rats against *Escherichia coli* induced cholangitis. *Gut* 1996;39(1):136-140.
93. Harmatz PR, Kleinman RE, Bunnell BW, Bloch KJ, Walker WA. Hepatobiliary clearance of IgA immune complexes formed in the circulation. *Hepatology* 1982;2(3):328-333.
94. Peppard JV, Orlans E, Andrew E, Payne AW. Elimination into bile of circulating antigen by endogenous IgA antibody in rats. *Immunology* 1982;45(3):467-472.
95. Mostov KE. Transepithelial transport of immunoglobulins. *Annu Rev Immunol* 1994;12:63-84.
96. Saito K, Nakanuma Y. Lactoferrin and lysozyme in the intrahepatic bile duct of normal livers and hepatolithiasis. An immunohistochemical study. *J Hepatol* 1992;15(1-2):147-153.
97. Harada K, Ohba K, Ozaki S, Isse K, Hirayama T, Wada A et al. Peptide antibiotic human beta-defensin-1 and -2 contribute to antimicrobial defense of the intrahepatic biliary tree. *Hepatology* 2004;40(4):925-932.
98. D'Aldebert E, Biyeyeme Bi Mve MJ, Mergey M, Wendum D, Firrincieli D, Coilly A et al. Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. *Gastroenterology* 2009;136(4):1435-1443.
99. Hu G, Gong AY, Roth AL, Huang BQ, Ward HD, Zhu G et al. Release of luminal exosomes contributes to TLR4-mediated epithelial antimicrobial defense. *PLoS Pathog* 2013;9(4):e1003261.
100. Nozaki I, Lunz JG, 3rd, Specht S, Park JI, Giraud AS, Murase N et al. Regulation and function of trefoil factor family 3 expression in the biliary tree. *Am J Pathol* 2004;165(6):1907-1920.
101. Sasaki M, Tsuneyama K, Saito T, Kataoka H, Mollenhauer J, Poustka A et al. Site-characteristic expression and induction of trefoil factor family 1, 2 and 3 and malignant brain tumor-1 in normal and diseased intrahepatic bile ducts relates to biliary pathophysiology. *Liver Int* 2004;24(1):29-37.
102. Sasaki M, Tsuneyama K, Nakanuma Y. Aberrant expression of trefoil factor family 1 in biliary epithelium in hepatolithiasis and cholangiocarcinoma. *Lab Invest* 2003;83(10):1403-1413.
103. Srivatsa G, Giraud AS, Ulaganathan M, Yeomans ND, Dow C, Nicoll AJ. Biliary epithelial trefoil peptide expression is increased in biliary diseases. *Histopathology* 2002;40(3):261-268.
104. Al-Masri AN, Flemming P, Rodeck B, Melter M, Leonhardt J, Petersen C. Expression of the interferon-induced Mx proteins in biliary atresia. *J Pediatr Surg* 2006;41(6):1139-1143.
105. Huang YH, Chou MH, Du YY, Huang CC, Wu CL, Chen CL et al. Expression of toll-like receptors and type 1 interferon specific protein MxA in biliary atresia. *Lab Invest* 2007;87(1):66-74.
106. Harada K, Sato Y, Itatsu K, Isse K, Ikeda H, Yasoshima M et al. Innate immune response to double-stranded RNA in biliary epithelial cells is associated with the pathogenesis of biliary atresia. *Hepatology* 2007;46(4):1146-1154.
107. Chen XM, O'Hara SP, Nelson JB, Splinter PL, Small AJ, Tietz PS et al. Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to *Cryptosporidium parvum* via activation of NF-kappaB. *J Immunol* 2005;175(11):7447-7456.
108. Bowdish DM, Davidson DJ, Hancock RE. Immunomodulatory properties of defensins and cathelicidins. *Curr Top Microbiol Immunol* 2006;306:27-66.

109. Morland CM, Fear J, Joplin R, Adams DH. Inflammatory cytokines stimulate human biliary epithelial cells to express interleukin-8 and monocyte chemotactic protein-1. *Biochem Soc Trans* 1997;25(2):232S.
110. Morland CM, Fear J, McNab G, Joplin R, Adams DH. Promotion of leukocyte transendothelial cell migration by chemokines derived from human biliary epithelial cells in vitro. *Proc Assoc Am Physicians* 1997;109(4):372-382.
111. Yokoyama T, Komori A, Nakamura M, Takii Y, Kamiyama T, Shimoda S et al. Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways. *Liver Int* 2006;26(4):467-476.
112. Matsumoto K, Fujii H, Michalopoulos G, Fung JJ, Demetris AJ. Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. *Hepatology* 1994;20(2):376-382.
113. Ayres RC, Neuberger JM, Shaw J, Joplin R, Adams DH. Intercellular adhesion molecule-1 and MHC antigens on human intrahepatic bile duct cells: effect of pro-inflammatory cytokines. *Gut* 1993;34(9):1245-1249.
114. Leon MP, Kirby JA, Gibbs P, Burt AD, Bassendine MF. Immunogenicity of biliary epithelial cells: study of the expression of B7 molecules. *J Hepatol* 1995;22(5):591-595.
115. Van Den Heuvel MC, Slooff MJ, Visser L, Muller M, De Jong KP, Poppema S et al. Expression of anti-OV6 antibody and anti-N-CAM antibody along the biliary line of normal and diseased human livers. *Hepatology* 2001;33(6):1387-1393.
116. Saidman SL, Duquesnoy RJ, Zeevi A, Fung JJ, Starzl TE, Demetris AJ. Recognition of major histocompatibility complex antigens on cultured human biliary epithelial cells by alloreactive lymphocytes. *Hepatology* 1991;13(2):239-246.
117. Leon MP, Bassendine MF, Gibbs P, Thick M, Kirby JA. Immunogenicity of biliary epithelium: study of the adhesive interaction with lymphocytes. *Gastroenterology* 1997;112(3):968-977.
118. Leon MP, Bassendine MF, Wilson JL, Ali S, Thick M, Kirby JA. Immunogenicity of biliary epithelium: investigation of antigen presentation to CD4+ T cells. *Hepatology* 1996;24(3):561-567.
119. Tsuneyama K, Harada K, Yasoshima M, Kaji K, Gershwin ME, Nakanuma Y. Expression of co-stimulatory factor B7-2 on the intrahepatic bile ducts in primary biliary cirrhosis and primary sclerosing cholangitis: an immunohistochemical study. *J Pathol* 1998;186(2):126-130.
120. Selmi C, Lleo A, Pasini S, Zuin M, Gershwin ME. Innate immunity and primary biliary cirrhosis. *Curr Mol Med* 2009;9(1):45-51.
121. Lombardi G, Sidhu S, Batchelor R, Lechler R. Anergic T cells as suppressor cells in vitro. *Science* 1994;264:1587-1589.
122. Savage CO, Brooks CJ, Harcourt GC, Picard JK, King W, Sansom DM et al. Human vascular endothelial cells process and present autoantigen to human T cell lines. *Int Immunol* 1995;7(3):471-479.
123. Barnes BH, Tucker RM, Wehrmann F, Mack DG, Ueno Y, Mack CL. Cholangiocytes as immune modulators in rotavirus-induced murine biliary atresia. *Liver Int* 2009;29(8):1253-1261.
124. Gong AY, Zhou R, Hu G, Li X, Splinter PL, O'Hara SP et al. MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. *J Immunol* 2009;182(3):1325-1333.
125. Demetris AJ, Jaffe R, Tzakis A, Ramsey G, Todo S, Belle S et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. *American Journal of Pathology* 1988;132(3):489-502.
126. Demetris AJ, Fontes P, Lunz JG, 3rd, Specht S, Murase N, Marcos A. Wound healing in the biliary tree of liver allografts. *Cell Transplant* 2006;15 Suppl 1:S57-65.
127. Knaak JM, Spetzler VN, Goldaracena N, Boehnert MU, Bazerbachi F, Louis KS et al. Subnormothermic ex vivo liver perfusion reduces endothelial cell and bile duct injury after donation after cardiac death pig liver transplantation. *Liver Transpl* 2014;20(11):1296-1305.

128. Taner CB, Bulatao IG, Willingham DL, Perry DK, Sibulesky L, Pungpapong S et al. Events in procurement as risk factors for ischemic cholangiopathy in liver transplantation using donation after cardiac death donors. *Liver Transpl* 2012;18(1):100-111.
129. Foley DP, Fernandez LA, Levenson G, Anderson M, Mezrich J, Sollinger HW et al. Biliary complications after liver transplantation from donation after cardiac death donors: an analysis of risk factors and long-term outcomes from a single center. *Ann Surg* 2011;253(4):817-825.
130. Noack K, Bronk SF, Kato A, Gores GJ. The greater vulnerability of bile duct cells to reoxygenation injury than to anoxia. Implications for the pathogenesis of biliary strictures after liver transplantation. *Transplantation* 1993;56(3):495-500.
131. Feng L, Pang L, Guo Y, Ke N, Li S, Wei L et al. Hypoxia/reoxygenation up-regulates death receptor expression and enhances apoptosis in human biliary epithelial cells. *Life Sci* 2009;85(9-10):401-407.
132. Kaneku H, O'Leary JG, Banuelos N, Jennings LW, Susskind BM, Klintmalm GB et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. *Am J Transplant* 2013;13(6):1541-1548.
133. Sanchez-Urdazpal L, Batts KP, Gores GJ, Moore SB, Sterioff S, Wiesner RH et al. Increased bile duct complications in liver transplantation across the ABO barrier. *Ann Surg* 1993;218(2):152-158.
134. Wu J, Ye S, Xu X, Xie H, Zhou L, Zheng S. Recipient outcomes after ABO-incompatible liver transplantation: a systematic review and meta-analysis. *PLoS One* 2011;6(1):e16521.
135. Iacob S, Cicinnati VR, Lindemann M, Heinemann FM, Radtke A, Kaiser GM et al. Donor-Specific Anti-HLA Antibodies and Endothelial C4d Deposition-Association With Chronic Liver Allograft Failure. *Transplantation* 2015;99(9):1869-1875.
136. Iacob S, Cicinnati VR, Dechêne A, Lindemann M, Heinemann FM, Rebmann V et al. Genetic, immunological and clinical risk factors for biliary strictures following liver transplantation. *Liver Int* 2012;32(8):1253-1261.
137. Abu-Elmagd KM, Wu G, Costa G, Lunz J, Martin L, Koritsky DA et al. Preformed and de novo donor specific antibodies in visceral transplantation: long-term outcome with special reference to the liver. *Am J Transplant* 2012;12(11):3047-3060.
138. Drachenberg CB, Papadimitriou JC. Endothelial injury in renal antibody-mediated allograft rejection: a schematic view based on pathogenesis. *Transplantation* 2013;95(9):1073-1083.
139. Valenzuela NM, McNamara JT, Reed EF. Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms. *Curr Opin Organ Transplant* 2014;19(1):33-40.
140. Ueno Y, Ishii M, Yahagi K, Mano Y, Kisara N, Nakamura N et al. Fas-mediated cholangiopathy in the murine model of graft versus host disease. *Hepatology* 2000;31(4):966-974.
141. Ahn EY, Pan G, Vickers SM, McDonald JM. IFN-gamma upregulates apoptosis-related molecules and enhances Fas-mediated apoptosis in human cholangiocarcinoma. *Int J Cancer* 2002;100(4):445-451.
142. Gapany C, Zhao M, Zimmermann A. The apoptosis protector, bcl-2 protein, is downregulated in bile duct epithelial cells of human liver allografts. *J Hepatol* 1997;26(3):535-542.
143. Afford SC, Ahmed-Choudhury J, Randhawa S, Russell C, Youster J, Crosby HA et al. CD40 activation-induced, Fas-dependent apoptosis and NF-kappaB/AP-1 signaling in human intrahepatic biliary epithelial cells. *Faseb J* 2001;15(13):2345-2354.
144. Yasoshima M, Kono N, Sugawara H, Katayanagi K, Harada K, Nakanuma Y. Increased expression of interleukin-6 and tumor necrosis factor-alpha in pathologic biliary epithelial cells: in situ and culture study. *Lab Invest* 1998;78(1):89-100.
145. Takeda K, Kojima Y, Ikejima K, Harada K, Yamashina S, Okumura K et al. Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. *Proc Natl Acad Sci U S A* 2008;105(31):10895-10900.

146. Demetris AJ, Lunz JG, 3rd, Specht S, Nozaki I. Biliary wound healing, ductular reactions, and IL-6/gp130 signaling in the development of liver disease. *World J Gastroenterol* 2006;12(22):3512-3522.
147. Verdonk RC, Buis CI, Porte RJ, van der Jagt EJ, Limburg AJ, van den Berg AP et al. Anastomotic biliary strictures after liver transplantation: causes and consequences. *Liver Transpl* 2006;12(5):726-735.
148. Verdonk RC, Buis CI, van der Jagt EJ, Gouw AS, Limburg AJ, Slooff MJ et al. Nonanastomotic biliary strictures after liver transplantation, part 2: Management, outcome, and risk factors for disease progression. *Liver Transpl* 2007;13(5):725-732.
149. Buis CI, Verdonk RC, Van der Jagt EJ, van der Hilst CS, Slooff MJ, Haagsma EB et al. Nonanastomotic biliary strictures after liver transplantation, part 1: Radiological features and risk factors for early vs. Late presentation. *Liver Transpl* 2007;13(5):708-718.
150. Nakanuma Y, Sasaki M, Harada K. Autophagy and senescence in fibrosing cholangiopathies. *J Hepatol* 2015;62(4):934-945.
151. Shirkoohi R. Epithelial mesenchymal transition from a natural gestational orchestration to a bizarre cancer disturbance. *Cancer Sci* 2013;104(1):28-35.
152. Redd MJ, Cooper L, Wood W, Stramer B, Martin P. Wound healing and inflammation: embryos reveal the way to perfect repair. *Philos Trans R Soc Lond B Biol Sci* 2004;359(1445):777-784.
153. Brunner SM, Junger H, Ruemmele P, Schnitzbauer AA, Doenecke A, Kirchner G et al. Bile duct damage after cold storage of deceased donor livers predicts biliary complications after liver transplantation. *J Hepatol* 2013;58(6):1133-1139.
154. Op den Dries S, Westerkamp AC, Karimian N, Gouw AS, Bruinsma BG, Markmann JF et al. Injury to peribiliary glands and vascular plexus before liver transplantation predicts formation of non-anastomotic biliary strictures. *J Hepatol* 2014.
155. Woolbright BL, Jaeschke H. Novel insight into mechanisms of cholestatic liver injury. *World J Gastroenterol* 2012;18(36):4985-4993.
156. Falasca L, Tisone G, Orlando G, Baiocchi L, Vennerecci G, Anselmo A et al. Tauroursodeoxycholate reduces ischemic damage in human allografts: a biochemical and ultrastructural study. *Transplant Proc* 2000;32(1):49-50.
157. Wang SY, Tang HM, Chen GQ, Xu JM, Zhong L, Wang ZW et al. Effect of ursodeoxycholic acid administration after liver transplantation on serum liver tests and biliary complications: a randomized clinical trial. *Digestion* 2012;86(3):208-217.
158. Kulaksiz H, Heuberger D, Engler S, Stiehl A. Poor outcome in progressive sclerosing cholangitis after septic shock. *Endoscopy* 2008;40(3):214-218.
159. Saxena R, Theise ND, Crawford JM. Microanatomy of the human liver-exploring the hidden interfaces. *Hepatology* 1999;30(6):1339-1346.
160. Matsumoto T, Kawakami M. The unit-concept of hepatic parenchyma--a re-examination based on angioarchitectural studies. *Acta Pathol Jpn* 1982;32 Suppl 2:285-314.
161. Ekataksin W, Zou Z, Wake K, Chunhabundit P, Somana R, Nishida J et al. The hepatic microcirculatory subunits: an over-three century- long search for the missing link between an exocrine unit and an endocrine unit in mammalian liver lobules. In: PM M, (ed). *Recent Advances in Microscopy of Cells, Tissues, and Organs*. Rome, Italy: University of Rome, La Sapienza Press, 1997: 375-380.
162. McCuskey RS. The hepatic microvascular system in health and its response to toxicants. *Anat Rec (Hoboken)* 2008;291(6):661-671.
163. Grabhorn E, Binder TM, Obrecht D, Brinkert F, Lehnhardt A, Herden U et al. Long-Term Clinical Relevance of De Novo Donor-Specific Antibodies After Pediatric Liver Transplantation. *Transplantation* 2015.

164. Wozniak LJ, Hickey MJ, Venick RS, Vargas JH, Farmer DG, Busuttil RW et al. Donor-Specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. *Transplantation* 2015.
165. Pappo O, Ramos H, Starzl TE, Fung JJ, Demetris AJ. - Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. *American Journal of Surgical Pathology* 1995;19(2):192-206.
166. Hubscher SG. What is the long-term outcome of the liver allograft? *Journal of Hepatology* 2011;55(3):702-717.
167. O'Leary JG, Cai J, Freeman R, Banuelos N, Hart B, Johnson M et al. Proposed Diagnostic Criteria for Chronic Antibody-Mediated Rejection in Liver Allografts. *Am J Transplant* 2015.
168. Wisse E. An ultrastructural characterization of the endothelial cell in the rat liver sinusoid under normal and various experimental conditions, as a contribution to the distinction between endothelial and Kupffer cells. *J Ultrastruct Res* 1972;38(5):528-562.
169. Lalor PF, Lai WK, Curbishley SM, Shetty S, Adams DH. Human hepatic sinusoidal endothelial cells can be distinguished by expression of phenotypic markers related to their specialised functions in vivo. *World J Gastroenterol* 2006;12(34):5429-5439.
170. Mouta Carreira C, Nasser SM, di Tomaso E, Padera TP, Boucher Y, Tomarev SI et al. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. *Cancer Res* 2001;61(22):8079-8084.
171. Ohtani O, Ohtani Y. Lymph circulation in the liver. *Anat Rec (Hoboken)* 2008;291(6):643-652.
172. Steffan AM, Gendrault JL, McCuskey RS, McCuskey PA, Kirn A. Phagocytosis, an unrecognized property of murine endothelial liver cells. *Hepatology* 1986;6(5):830-836.
173. Sørensen KK, McCourt P, Berg T, Crossley C, Le Couteur D, Wake K et al. The scavenger endothelial cell: a new player in homeostasis and immunity. *Am J Physiol Regul Integr Comp Physiol* 2012;303(12):R1217-1230.
174. Shiratori Y, Tanaka M, Kawase T, Shiina S, Komatsu Y, Omata M. Quantification of sinusoidal cell function in vivo. *Semin Liver Dis* 1993;13(1):39-49.
175. Fraser R, Cogger VC, Dobbs B, Jamieson H, Warren A, Hilmer SN et al. The liver sieve and atherosclerosis. *Pathology* 2012;44(3):181-186.
176. Brunt EM, Gouw AS, Hubscher SG, Tiniakos DG, Bedossa P, Burt AD et al. Pathology of the liver sinusoids. *Histopathology* 2014;64(7):907-920.
177. Deleve LD, Wang X, Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. *Hepatology* 2008;48(3):920-930.
178. Xu B, Broome U, Uzunel M, Nava S, Ge X, Kumagai-Braesch M et al. Capillarization of hepatic sinusoid by liver endothelial cell-reactive autoantibodies in patients with cirrhosis and chronic hepatitis. *Am J Pathol* 2003;163(4):1275-1289.
179. Nalbantoglu IL, Tan BR, Linehan DC, Gao F, Brunt EM. Histological features and severity of oxaliplatin-induced liver injury and clinical associations. *J Dig Dis* 2014;15(10):553-560.
180. Narita M, Oussoultzoglou E, Chenard MP, Fuchshuber P, Rather M, Rosso E et al. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization. *Ann Surg Oncol* 2012;19(7):2230-2237.
181. Cogger VC, Muller M, Fraser R, McLean AJ, Khan J, Le Couteur DG. The effects of oxidative stress on the liver sieve. *J Hepatol* 2004;41(3):370-376.
182. Le Couteur DG, Warren A, Cogger VC, Smedsrød B, Sørensen KK, De Cabo R et al. Old age and the hepatic sinusoid. *Anat Rec (Hoboken)* 2008;291(6):672-683.
183. McLean AJ, Cogger VC, Chong GC, Warren A, Markus AM, Dahlstrom JE et al. Age-related pseudocapillarization of the human liver. *J Pathol* 2003;200(1):112-117.
184. Hahn E, Wick G, Pencev D, Timpl R. Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin, and fibronectin. *Gut* 1980;21(1):63-71.
185. Noguchi K, Yagihashi A, Kobayashi M, Yoshida Y, Tanaka K, Konno A et al. Capillarization of the hepatic sinusoid in failed liver grafts. *Transplantation Proceedings* 1993;25(1 Pt 2):1110.

186. Feng S, Demetris AJ, Ekong U, Girnita A, Kanaparthi S, Soppe C et al. Serum and Tissue DSA Subclass, Stellate and Endothelial Phenotype Monitoring in ITN029ST Tolerance Pediatric Liver Transplant Recipients over 5+ Years of Follow-up. In: Joint International Conference of ILTS, ELITA & LICAGE; 2014; London; 2014.
187. Hirabaru M, Mochizuki K, Takatsuki M, Soyama A, Kosaka T, Kuroki T et al. Expression of alpha smooth muscle actin in living donor liver transplant recipients. *World J Gastroenterol* 2014;20(22):7067-7074.
188. Magari S, Fujikawa K, Nishi A. Form, distribution, fine structure and function of hepatic lymphatics with special reference to blood vessels and bile ducts. *Asian Medical Journal* 1981:254-270.
189. Magari S, Fujikawa K, Mizutani Y, Nishi A. Morphological studies on liver lymphatics. *Lymphology* 1979;12(1):14-17.
190. Trutmann M, Sasse D. The lymphatics of the liver. *Anat Embryol (Berl)* 1994;190(3):201-209.
191. Comparini L. Lymph vessels in the liver in man. *Angiologica* 1969;6:262-274.
192. Yamamoto K, Phillips MJ. Three-dimensional observation of the intrahepatic lymphatics by scanning electron microscopy of corrosion casts. *Anatomical Record* 1986;214(1):67-70.
193. Chung C, Iwakiri Y. The lymphatic vascular system in liver diseases: its role in ascites formation. *Clin Mol Hepatol* 2013;19(2):99-104.
194. Russo E, Nitschké M, Halin C. Dendritic cell interactions with lymphatic endothelium. *Lymphat Res Biol* 2013;11(3):172-182.
195. Yu B, Ueta H, Kitazawa Y, Tanaka T, Adachi K, Kimura H et al. Two immunogenic passenger dendritic cell subsets in the rat liver have distinct trafficking patterns and radiosensitivities. *Hepatology* 2012;56(4):1532-1545.
196. Marincek B, Barbier PA, Becker CD, Mettler D, Ruchti C. CT appearance of impaired lymphatic drainage in liver transplants. *AJR Am J Roentgenol* 1986;147(3):519-523.
197. Demetris AJ, Qian S, Sun H, Fung JJ, Yagihashi A, Murase N et al. Early events in liver allograft rejection. Delineation of sites of simultaneous intra-graft and recipient lymphoid tissue sensitization. *Am J Pathol* 1991;138(3):609-618.
198. Yamada H, Kondou H, Kimura T, Ikeda K, Tachibana M, Hasegawa Y et al. Humoral immunity is involved in the development of pericentral fibrosis after pediatric live donor liver transplantation. *Pediatr Transplant* 2012;16(8):858-865.
199. O'Leary JG, Kaneku H, Jennings L, Susskind BM, Terasaki PI, Klintmalm GB. Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients. *Liver Transpl* 2014;20(6):655-663.
200. O'Leary J, Kaneku H, Banuelos N, Jennings L, Klintmalm G, Terasaki P. Impact of IgG3 subclass and C1q-fixing donor specific antibodies on rejection and survival in liver transplantation. *American Journal of Transplantation* 2015;(in press).
201. O'Leary JG, Klintmalm GB. Impact of donor-specific antibodies on results of liver transplantation. *Curr Opin Organ Transplant* 2013;18(3):279-284.
202. Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ. The detailed distribution of HLA-A, B, C antigens in normal human organs. *Transplantation* 1984;38(3):287-292.
203. Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ. The detailed distribution of MHC Class II antigens in normal human organs. *Transplantation* 1984;38(3):293-298.
204. Lautenschlager I, Taskinen E, Inkinen K, Lehto VP, Virtanen I, Hayry P. Distribution of the major histocompatibility complex antigens on different cellular components of human liver. *Cellular Immunology* 1984;85(1):191-200.
205. Demetris AJ, Lasky S, Van Thiel DH, Starzl TE, Whiteside T. Induction of DR/IA antigens in human liver allografts. An immunocytochemical and clinicopathologic analysis of twenty failed grafts. *Transplantation* 1985;40(5):504-509.

206. Ballardini G, Bianchi FB, Mirakian R, Fallani M, Pisi E, Bottazzo GF. HLA-A,B,C, HLA-D/DR and HLA-D/DQ expression on unfixed liver biopsy sections from patients with chronic liver disease. *Clinical & Experimental Immunology* 1987;70(1):35-46.
207. Barbatis C, Kelly P, Greveson J, Heryet A, McGee JO. Immunocytochemical analysis of HLA class II (DR) antigens in liver disease in man. *Journal of Clinical Pathology* 1987;40(8):879-884.
208. Steinhoff G, Wonigeit K, Pichlmayr R. Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. *Transplantation* 1988;45(2):394-401.
209. Gouw AS, Huitema S, Grond J, Slooff MJ, Klompmaker IJ, Gips CH et al. Early induction of MHC antigens in human liver grafts. An immunohistologic study. *Am J Pathol* 1988;133(1):82-94.
210. Steinhoff G. Major histocompatibility complex antigens in human liver transplants. *J Hepatol* 1990;11(1):9-15.
211. Hubscher SG, Adams DH, Elias E. Changes in the expression of major histocompatibility complex class II antigens in liver allograft rejection. *J Pathol* 1990;162(2):165-171.
212. Terada T, Nakanuma Y, Obata H. HLA-DR expression on the microvasculature of portal tracts in idiopathic portal hypertension. Immunohistochemical characteristics and relation to portal phlebosclerosis. *Arch Pathol Lab Med* 1991;115(10):993-997.
213. Rouger P, Poupon R, Gane P, Mallissen B, Darnis F, Salmon C. Expression of blood group antigens including HLA markers in human adult liver. *Tissue Antigens* 1986;27(2):78-86.
214. Gugenheim J, Rouger P, Gane P, Capron-Laudereau M, Reynes M, Bismuth H. Expression of blood group antigens including HLA markers on human liver allografts. *Transplant Proc* 1987;19(1 Pt 1):223-225.
215. Terada T, Nakanuma Y, Hosono M, Obata H. Expression of HLA-DR antigen on hepatic vascular endothelial cells in idiopathic portal hypertension. *Clin Exp Immunol* 1991;84(2):303-307.
216. Muczynski KA, Ekle DM, Coder DM, Anderson SK. Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. *J Am Soc Nephrol* 2003;14(5):1336-1348.
217. Page C, Rose M, Yacoub M, Pigott R. Antigenic heterogeneity of vascular endothelium. *Am J Pathol* 1992;141(3):673-683.
218. Knolle PA, Uhrig A, Hegenbarth S, Löser E, Schmitt E, Gerken G et al. IL-10 down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells through decreased antigen uptake via the mannose receptor and lowered surface expression of accessory molecules. *Clin Exp Immunol* 1998;114(3):427-433.
219. Knolle P, Schlaak J, Uhrig A, Kempf P, Meyer zum Büschenfelde KH, Gerken G. Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. *J Hepatol* 1995;22(2):226-229.
220. Valenzuela NM, Mulder A, Reed EF. HLA class I antibodies trigger increased adherence of monocytes to endothelial cells by eliciting an increase in endothelial P-selectin and, depending on subclass, by engaging FcγRs. *J Immunol* 2013;190(12):6635-6650.
221. Valenzuela NM, Reed EF. Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. *Methods Mol Biol* 2013;1034:41-70.
222. Lee SJ, Qin H, Benveniste EN. The IFN-γ-induced transcriptional program of the CIITA gene is inhibited by statins. *Eur J Immunol* 2008;38(8):2325-2336.
223. Nandan D, Reiner NE. TGF-β attenuates the class II transactivator and reveals an accessory pathway of IFN-γ action. *J Immunol* 1997;158(3):1095-1101.
224. Porter KA. Pathology of liver transplantation. *Transplant Rev* 1969;2:129-170.
225. Starzl TE, Demetris AJ, Trucco M, Murase N, Ricordi C, Ildstad S et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. *Hepatology* 1993;17(6):1127-1152.

226. Gouw AS, Houthoff HJ, Huitema S, Beelen JM, Gips CH, Poppema S. Expression of major histocompatibility complex antigens and replacement of donor cells by recipient ones in human liver grafts. *Transplantation* 1987;43(2):291-296.
227. Portmann B, Schindler AM, Murray-Lyon IM, Williams R. Histological sexing of a reticulum cell sarcoma arising after liver transplantation. *Gastroenterology* 1976;70(1):82-84.
228. Clouston AD, Jonsson JR, Balderson GA, Fawcett J, Lynch SV, Kelso A et al. Lymphocyte apoptosis and cell replacement in human liver allografts. *Transplantation* 2002;73(11):1828-1834.
229. Ng IO, Chan KL, Shek WH, Lee JM, Fong DY, Lo CM et al. High frequency of chimerism in transplanted livers. *Hepatology* 2003;38(4):989-998.
230. Starzl TE, Demetris AJ, Trucco M, Ramos H, Zeevi A, Rudert WA et al. Systemic chimerism in human female recipients of male livers. *Lancet* 1992;340(8824):876-877.
231. Guillelliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. *Nat Rev Immunol* 2014;14(8):571-578.
232. Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. *Cell* 2014;159(6):1312-1326.
233. Brenner DA, Kisseleva T, Scholten D, Paik YH, Iwaisako K, Inokuchi S et al. Origin of myofibroblasts in liver fibrosis. *Fibrogenesis Tissue Repair* 2012;5(Suppl 1):S17.
234. Kisseleva T, Brenner DA. The phenotypic fate and functional role for bone marrow-derived stem cells in liver fibrosis. *J Hepatol* 2012;56(4):965-972.
235. Forbes SJ, Russo FP, Rey V, Burra P, Rugge M, Wright NA et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. *Gastroenterology* 2004;126(4):955-963.
236. Theise ND, Nimmakayalu M, Gardner R, Illei PB, Morgan G, Teperman L et al. Liver from bone marrow in humans. *Hepatology* 2000;32(1):11-16.
237. Hove WR, van Hoek B, Bajema IM, Ringers J, van Krieken JH, Lagaij EL. Extensive chimerism in liver transplants: vascular endothelium, bile duct epithelium, and hepatocytes. *Liver Transpl* 2003;9(6):552-556.
238. Wu T, Cieply K, Nalesnik MA, Randhawa PS, Sonzogni A, Bellamy C et al. Minimal evidence of transdifferentiation from recipient bone marrow to parenchymal cells in regenerating and long-surviving human allografts. *Am J Transplant* 2003;3(9):1173-1181.
239. Pilat N, Schoppmann S, Stift J, Mazal P, Wekerle T, Berlakovich GA. No evidence for recipient-derived hepatocytes in serial biopsies of sex-mismatched liver transplants. *Transplantation* 2012;94(9):953-957.
240. Wagers AJ, Sherwood RI, Christensen JL, Weissman IL. Little evidence for developmental plasticity of adult hematopoietic stem cells. *Science* 2002;297(5590):2256-2259.
241. Tanaka Y, Haga H, Egawa H, Okuno T, Miyagawa-Hayashino A, Tsuruyama T et al. Intragraft expression of recipient-type ABO blood group antigens: long-term follow-up and histological features after liver transplantation. *Liver Transpl* 2005;11(5):547-554.
242. Kashiwagi N, Porter KA, Penn I, Brettschneider L, Starzl TE. Studies of homograft sex and of gamma globulin phenotypes after orthotopic homotransplantation of the human liver. *Surg Forum* 1969;20:374-376.
243. Pons JA, Yelamos J, Ramirez P, Oliver-Bonet M, Sanchez A, Rodriguez-Gago M et al. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. *Transplantation* 2003;75(7):1045-1047.
244. Bataller R, Brenner DA. Liver fibrosis. *J Clin Invest* 2005;115(2):209-218.
245. Gandhi CR. Hepatic Stellate Cells. In "Molecular Pathology of Liver Diseases" (SP Monga, ed) Springer 2010:53-80.
246. Hasegawa D, Wallace, M.C., and Friedman, S.L. Stellate cells and hepatic fibrosis. In "Stellate cells in Health and Disease" (Gandhi CR, Pinzani M, eds), Elsevier 2015:41-62.

247. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. *Annu Rev Pathol* 2011;6:425-456.
248. Kent G, Inouye T, Minick OT, Bahu RM. Fat-storing cells (lipocytes) in the liver: their role in vitamin A storage and fibrogenesis. *Med Chir Dig* 1977;6(7):425-428.
249. McGee JO, Patrick RS. The role of perisinusoidal cells in experimental hepatic fibrogenesis. *J Pathol* 1972;106(1):Pvi.
250. McGee JO, Patrick RS. The role of perisinusoidal cells in hepatic fibrogenesis. An electron microscopic study of acute carbon tetrachloride liver injury. *Lab Invest* 1972;26(4):429-440.
251. Wake K. Liver perivascular cells revealed by gold and silver impregnation methods and electron microscopy. In: Motta P, ed *Biopathology of the liver, an ultrastructural approach* Dordrecht : Kluwer; 1988:23-26.
252. Senoo H, Kojima N, Sato M. Vitamin A-storing cells (stellate cells). *Vitam Horm* 2007;75:131-159.
253. Senoo H, Yoshikawa K, Morii M, Miura M, Imai K, Mezaki Y. Hepatic stellate cell (vitamin A-storing cell) and its relative--past, present and future. *Cell Biol Int* 2010;34(12):1247-1272.
254. Puche JE, Lee YA, Jiao J, Aloman C, Fiel MI, Munoz U et al. A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice. *Hepatology* 2013;57(1):339-350.
255. Hammerich L, Tacke F. Emerging roles of myeloid derived suppressor cells in hepatic inflammation and fibrosis. *World J Gastrointest Pathophysiol* 2015;6(3):43-50.
256. Kisseleva T, Brenner DA. Fibrogenesis of parenchymal organs. *Proc Am Thorac Soc* 2008;5(3):338-342.
257. Iwaisako K, Jiang C, Zhang M, Cong M, Moore-Morris TJ, Park TJ et al. Origin of myofibroblasts in the fibrotic liver in mice. *Proc Natl Acad Sci U S A* 2014;111(32):E3297-3305.
258. Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. *Nat Commun* 2013;4:2823.
259. Michelotti GA, Xie G, Swiderska M, Choi SS, Karaca G, Kruger L et al. Smoothed is a master regulator of adult liver repair. *J Clin Invest* 2013;123(6):2380-2394.
260. Albanis E, Friedman SL. Antifibrotic agents for liver disease. *Am J Transplant* 2006;6(1):12-19.
261. Ghiassi-Nejad Z, Friedman SL. Advances in antifibrotic therapy. *Expert Rev Gastroenterol Hepatol* 2008;2(6):803-816.
262. Lotersztajn S, and Mallat, A. Hepatic stellate cells as target for reversal of fibrosis/cirrhosis. In "Stellate cells in Health and Disease" (Gandhi CR, Pinzani M, eds), Elsevier 2015:175-184.
263. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. *Semin Liver Dis* 2001;21(3):311-335.
264. May D, Djonov V, Zamir G, Bala M, Safadi R, Sklair-Levy M et al. A transgenic model for conditional induction and rescue of portal hypertension reveals a role of VEGF-mediated regulation of sinusoidal fenestrations. *PLoS One* 2011;6(7):e21478.
265. Xie G, Wang X, Wang L, Atkinson RD, Kanel GC, Gaarde WA et al. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. *Gastroenterology* 2012;142(4):918-927 e916.
266. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. *Hepatology* 1988;8(2):232-236.
267. Riordan SM, Skinner N, Nagree A, McCallum H, McIver CJ, Kurtovic J et al. Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. *Hepatology* 2003;37(5):1154-1164.
268. Kendall TJ, Henedige S, Aucott RL, Hartland SN, Vernon MA, Benyon RC et al. p75 Neurotrophin receptor signaling regulates hepatic myofibroblast proliferation and apoptosis in recovery from rodent liver fibrosis. *Hepatology* 2009;49(3):901-910.

269. Sachs BD, Baillie GS, McCall JR, Passino MA, Schachtrup C, Wallace DA et al. p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway. *J Cell Biol* 2007;177(6):1119-1132.
270. Kocabayoglu P, Friedman SL. Cellular basis of hepatic fibrosis and its role in inflammation and cancer. *Front Biosci (Schol Ed)* 2013;5:217-230.
271. Novo E, Busletta C, Bonzo LV, Povero D, Paternostro C, Mareschi K et al. Intracellular reactive oxygen species are required for directional migration of resident and bone marrow-derived hepatic pro-fibrogenic cells. *J Hepatol* 2011;54(5):964-974.
272. Paik YH, Iwaisako K, Seki E, Inokuchi S, Schnabl B, Osterreicher CH et al. The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice. *Hepatology* 2011;53(5):1730-1741.
273. Marra F, Romanelli RG, Giannini C, Failli P, Pastacaldi S, Arrighi MC et al. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. *Hepatology* 1999;29(1):140-148.
274. Melton AC, Yee HF. Hepatic stellate cell protrusions couple platelet-derived growth factor-BB to chemotaxis. *Hepatology* 2007;45(6):1446-1453.
275. Novo E, Cannito S, Zamara E, Valfre di Bonzo L, Caligiuri A, Cravanzola C et al. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. *Am J Pathol* 2007;170(6):1942-1953.
276. Friedman SL, Arthur MJ. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. *J Clin Invest* 1989;84(6):1780-1785.
277. Pinzani M, Gesualdo L, Sabbah GM, Abboud HE. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. *J Clin Invest* 1989;84(6):1786-1793.
278. Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. *Compr Physiol* 2013;3(4):1473-1492.
279. Canbay A, Higuchi H, Bronk SF, Tanai M, Sebo TJ, Gores GJ. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. *Gastroenterology* 2002;123(4):1323-1330.
280. Czaja MJ, Geerts A, Xu J, Schmiedeberg P, Ju Y. Monocyte chemoattractant protein 1 (MCP-1) expression occurs in toxic rat liver injury and human liver disease. *J Leukoc Biol* 1994;55(1):120-126.
281. Harvey SA, Dangi A, Tandon A, Gandhi CR. The transcriptomic response of rat hepatic stellate cells to endotoxin: implications for hepatic inflammation and immune regulation. *PLoS One* 2013;8(12):e82159.
282. Marra F, Valente AJ, Pinzani M, Abboud HE. Cultured human liver fat-storing cells produce monocyte chemotactic protein-1. Regulation by proinflammatory cytokines. *J Clin Invest* 1993;92(4):1674-1680.
283. Muhlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. *Gastroenterology* 2003;125(4):1085-1093.
284. Sprenger H, Kaufmann A, Garn H, Lahme B, Gerns D, Gressner AM. Differential expression of monocyte chemotactic protein-1 (MCP-1) in transforming rat hepatic stellate cells. *J Hepatol* 1999;30(1):88-94.
285. Thirunavukkarasu C, Uemura T, Wang LF, Watkins SC, Gandhi CR. Normal rat hepatic stellate cells respond to endotoxin in LBP-independent manner to produce inhibitor(s) of DNA synthesis in hepatocytes. *J Cell Physiol* 2005;204(2):654-665.
286. Thirunavukkarasu C, Watkins SC, Gandhi CR. Mechanisms of endotoxin-induced NO, IL-6, and TNF-alpha production in activated rat hepatic stellate cells: role of p38 MAPK. *Hepatology* 2006;44(2):389-398.

287. Dangi A, Sumpter TL, Kimura S, Stolz DB, Murase N, Raimondi G et al. Selective expansion of allogeneic regulatory T cells by hepatic stellate cells: role of endotoxin and implications for allograft tolerance. *J Immunol* 2012;188(8):3667-3677.
288. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. *Nat Med* 2007;13(11):1324-1332.
289. Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. *Am J Pathol* 1998;152(2):423-430.
290. Marra F, Grandaliano G, Valente AJ, Abboud HE. Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury. *Hepatology* 1995;22(3):780-787.
291. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfecting patients. The Multivirc Group. *Hepatology* 1999;30(4):1054-1058.
292. Muhanna N, Horani A, Doron S, Safadi R. Lymphocyte-hepatic stellate cell proximity suggests a direct interaction. *Clin Exp Immunol* 2007;148(2):338-347.
293. Schwabe RF, Bataller R, Brenner DA. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. *Am J Physiol Gastrointest Liver Physiol* 2003;285(5):G949-958.
294. Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. *Gastroenterology* 2012;143(3):765-776 e761-763.
295. Campana L, and Iredale J. Matrix metalloproteinases and their inhibitors. In "Stellate cells in Health and Disease" (Gandhi CR, Pinzani M, eds), Elsevier 2015:107-124.
296. Gawrieh S, Papouchado BG, Burgart LJ, Kobayashi S, Charlton MR, Gores GJ. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. *Liver Transpl* 2005;11(10):1207-1213.
297. Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. *Proc Natl Acad Sci U S A* 2012;109(24):9448-9453.
298. Oakley F, Meso M, Iredale JP, Green K, Marek CJ, Zhou X et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. *Gastroenterology* 2005;128(1):108-120.
299. Anselmi K, Subbotin VM, Nemoto E, Gandhi CR. Accelerated reversal of carbon tetrachloride-induced cirrhosis in rats by the endothelin receptor antagonist TAK-044. *J Gastroenterol Hepatol* 2002;17(5):589-597.
300. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. *J Clin Invest* 1998;102(3):538-549.
301. Issa R, Williams E, Trim N, Kendall T, Arthur MJ, Reichen J et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. *Gut* 2001;48(4):548-557.
302. Issa R, Zhou X, Constandinou CM, Fallowfield J, Millward-Sadler H, Gaca MD et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. *Gastroenterology* 2004;126(7):1795-1808.
303. Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. *Gastroenterology* 2002;122(5):1525-1528.
304. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. *J Hepatol* 2004;40(4):646-652.
305. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. *Hepatology* 2004;39(6):1647-1654.

306. Hammel P, Couvelard A, O'Toole D, Ratouis A, Sauvanet A, Flejou JF et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. *N Engl J Med* 2001;344(6):418-423.
307. Kweon YO, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burchardt E et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. *J Hepatol* 2001;35(6):749-755.
308. Schaffner F, Poper H. Capillarization of hepatic sinusoids in man. *Gastroenterology* 1963;44:239-242.
309. Gandhi CR. Stellate cells in Hepatic Immunological Tolerance. In "Stellate Cells in Health and Disease" (Gandhi CR and Pinzani M, eds), Elsevier Press, 2015:227-249.
310. Kobayashi S, Seki S, Kawada N, Morikawa H, Nakatani K, Uyama N et al. Apoptosis of T cells in the hepatic fibrotic tissue of the rat: a possible inducing role of hepatic myofibroblast-like cells. *Cell Tissue Res* 2003;311(3):353-364.
311. Uemura T, Gandhi CR. Inhibition of DNA synthesis in cultured hepatocytes by endotoxin-conditioned medium of activated stellate cells is transforming growth factor-beta and nitric oxide-independent. *Br J Pharmacol* 2001;133(7):1125-1133.
312. Roland CR, Mangino MJ, Duffy BF, Flye MW. Lymphocyte suppression by Kupffer cells prevents portal venous tolerance induction: a study of macrophage function after intravenous gadolinium. *Transplantation* 1993;55(5):1151-1158.
313. Roland CR, Walp L, Stack RM, Flye MW. Outcome of Kupffer cell antigen presentation to a cloned murine Th1 lymphocyte depends on the inducibility of nitric oxide synthase by IFN-gamma. *J Immunol* 1994;153(12):5453-5464.
314. Dranoff JA, Wells RG. Portal fibroblasts: Underappreciated mediators of biliary fibrosis. *Hepatology* 2010;51(4):1438-1444.
315. Wen JW, Olsen AL, Perepelyuk M, Wells RG. Isolation of rat portal fibroblasts by in situ liver perfusion. *J Vis Exp* 2012(64):pii:3669.
316. Onitsuka I, Tanaka M, Miyajima A. Characterization and functional analyses of hepatic mesothelial cells in mouse liver development. *Gastroenterology* 2010;138(4):1525-1535, 1535 e1521-1526.
317. Ramadori G, Saile B. Inflammation, damage repair, immune cells, and liver fibrosis: specific or nonspecific, this is the question. *Gastroenterology* 2004;127(3):997-1000.
318. Ramadori G, Saile B. Portal tract fibrogenesis in the liver. *Lab Invest* 2004;84(2):153-159.
319. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. *Nat Rev Cancer* 2013;13(10):739-752.
320. Poschke I, Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. *Clin Immunol* 2012;144(3):250-268.
321. Cai W, Qin A, Guo P, Yan D, Hu F, Yang Q et al. Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients. *J Clin Immunol* 2013;33(4):798-808.
322. Kong X, Sun R, Chen Y, Wei H, Tian Z. gammadeltaT cells drive myeloid-derived suppressor cell-mediated CD8+ T cell exhaustion in hepatitis B virus-induced immunotolerance. *J Immunol* 2014;193(4):1645-1653.
323. Tacke RS, Lee HC, Goh C, Courtney J, Polyak SJ, Rosen HR et al. Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species. *Hepatology* 2012;55(2):343-353.
324. Kapanadze T, Gamrekelashvili J, Ma C, Chan C, Zhao F, Hewitt S et al. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. *J Hepatol* 2013;59(5):1007-1013.
325. Yen BL, Yen ML, Hsu PJ, Liu KJ, Wang CJ, Bai CH et al. Multipotent human mesenchymal stromal cells mediate expansion of myeloid-derived suppressor cells via hepatocyte growth factor/c-met and STAT3. *Stem Cell Reports* 2013;1(2):139-151.

326. Hochst B, Schildberg FA, Sauerborn P, Gabel YA, Gevensleben H, Goltz D et al. Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion. *J Hepatol* 2013;59(3):528-535.
327. Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. *Eur J Immunol* 2010;40(11):2969-2975.
328. Suh YG, Kim JK, Byun JS, Yi HS, Lee YS, Eun HS et al. CD11b(+) Gr1(+) bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice. *Hepatology* 2012;56(5):1902-1912.
329. Zhu K, Zhang N, Guo N, Yang J, Wang J, Yang C et al. SSC(high)CD11b(high)Ly-6C(high)Ly-6G(low) myeloid cells curtail CD4 T cell response by inducible nitric oxide synthase in murine hepatitis. *Int J Biochem Cell Biol* 2014;54:89-97.
330. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. *Nature* 2013;496(7446):445-455.
331. Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis. *J Hepatol* 2014;60(5):1090-1096.
332. Zimmermann HW, Trautwein C, Tacke F. Functional role of monocytes and macrophages for the inflammatory response in acute liver injury. *Front Physiol* 2012;3:56.
333. Schroder K, Irvine KM, Taylor MS, Bokil NJ, Le Cao KA, Masterman KA et al. Conservation and divergence in Toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages. *Proc Natl Acad Sci U S A* 2012;109(16):E944-953.
334. Shay T, Jojic V, Zuk O, Rothamel K, Puyraimond-Zemmour D, Feng T et al. Conservation and divergence in the transcriptional programs of the human and mouse immune systems. *Proc Natl Acad Sci U S A* 2013;110(8):2946-2951.
335. Fairbairn L, Kapetanovic R, Sester DP, Hume DA. The mononuclear phagocyte system of the pig as a model for understanding human innate immunity and disease. *J Leukoc Biol* 2011;89(6):855-871.
336. Raes G, Van den Bergh R, De Baetselier P, Ghassabeh GH, Scotton C, Locati M et al. Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. *J Immunol* 2005;174(11):6561; author reply 6561-6562.
337. Hume DA, Freeman TC. Transcriptomic analysis of mononuclear phagocyte differentiation and activation. *Immunol Rev* 2014;262(1):74-84.
338. Raza S, Barnett MW, Barnett-Itzhaki Z, Amit I, Hume DA, Freeman TC. Analysis of the transcriptional networks underpinning the activation of murine macrophages by inflammatory mediators. *J Leukoc Biol* 2014;96(2):167-183.
339. Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. *Nat Immunol* 2012;13(11):1118-1128.
340. Becher B, Schlitzer A, Chen J, Mair F, Sumatoh HR, Teng KW et al. High-dimensional analysis of the murine myeloid cell system. *Nat Immunol* 2014;15(12):1181-1189.
341. Jenkins SJ, Hume DA. Homeostasis in the mononuclear phagocyte system. *Trends Immunol* 2014;35(8):358-367.
342. Pettersen JS, Fuentes-Duculan J, Suarez-Farinas M, Pierson KC, Pitts-Kiefer A, Fan L et al. Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. *J Invest Dermatol* 2011;131(6):1322-1330.
343. Blieriot C, Dupuis T, Jouvion G, Eberl G, Disson O, Lecuit M. Liver-resident macrophage necroptosis orchestrates type 1 microbicidal inflammation and type-2-mediated tissue repair during bacterial infection. *Immunity* 2015;42(1):145-158.
344. Heymann F, Peusquens J, Ludwig-Portugall I, Kohlhepp M, Ergen C, Niemietz P et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. *Hepatology* 2015;62(1):279-291.
345. Fogg DK, Sibon C, Miled C, Jung S, Aucouturier P, Littman DR et al. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. *Science* 2006;311(5757):83-87.

346. Vu Manh TP, Elhmouzi-Younes J, Urien C, Ruscanu S, Jouneau L, Bourge M et al. Defining Mononuclear Phagocyte Subset Homology Across Several Distant Warm-Blooded Vertebrates Through Comparative Transcriptomics. *Front Immunol* 2015;6:299.
347. Bosma BM, Metselaar HJ, Mancham S, Boor PP, Kusters JG, Kazemier G et al. Characterization of human liver dendritic cells in liver grafts and perfusates. *Liver Transpl* 2006;12(3):384-393.
348. Uwatoku R, Suematsu M, Ezaki T, Saiki T, Tsuiji M, Irimura T et al. Kupffer cell-mediated recruitment of rat dendritic cells to the liver: roles of N-acetylgalactosamine-specific sugar receptors. *Gastroenterology* 2001;121(6):1460-1472.
349. Matsuno K, Nomiyama H, Yoneyama H, Uwatoku R. Kupffer cell-mediated recruitment of dendritic cells to the liver crucial for a host defense. *Dev Immunol* 2002;9(3):143-149.
350. Matsuno K, Ezaki T. Dendritic cell dynamics in the liver and hepatic lymph. *Int Rev Cytol* 2000;197:83-136.
351. Sato T, Yamamoto H, Sasaki C, Wake K. Maturation of rat dendritic cells during intrahepatic translocation evaluated using monoclonal antibodies and electron microscopy. *Cell Tissue Res* 1998;294(3):503-514.
352. Prickett TC, McKenzie JL, Hart DN. Characterization of interstitial dendritic cells in human liver. *Transplantation* 1988;46(5):754-761.
353. Bamboat ZM, Stableford JA, Plitas G, Burt BM, Nguyen HM, Welles AP et al. Human liver dendritic cells promote T cell hyporesponsiveness. *J Immunol* 2009;182(4):1901-1911.
354. Sumpter TL, Lunz IJ, Castellana A, Matta B, Tokita D, Turnquist HR et al. Dendritic cell immunobiology in relation to liver transplant outcome. *Front Biosci (Elite Ed)* 2009;1:99-114.
355. Schildberg FA, Hegenbarth SI, Schumak B, Scholz K, Limmer A, Knolle PA. Liver sinusoidal endothelial cells veto CD8 T cell activation by antigen-presenting dendritic cells. *Eur J Immunol* 2008;38(4):957-967.
356. Kwekkeboom J, Boor PP, Sen E, Kusters JG, Drexhage HA, de Jong EC et al. Human liver myeloid dendritic cells mature in vivo into effector DC with a poor allogeneic T-cell stimulatory capacity. *Transplant Proc* 2005;37(1):15-16.
357. Goddard S, Youster J, Morgan E, Adams DH. Interleukin-10 secretion differentiates dendritic cells from human liver and skin. *Am J Pathol* 2004;164(2):511-519.
358. Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. *Nat Rev Immunol* 2015;15(8):471-485.
359. Crispe IN. Liver antigen-presenting cells. *Journal of Hepatology* 2011;54(2):357-365.
360. Okuda T, Ishikawa T, Azhipa O, Ichikawa N, Demetris AJ, Starzl TE et al. Early passenger leukocyte migration and acute immune reactions in the rat recipient spleen during liver engraftment: with particular emphasis on donor major histocompatibility complex class II+ cells. *Transplantation* 2002;74(1):103-111.
361. Benseler V, McCaughan GW, Schlitt HJ, Bishop GA, Bowen DG, Bertolino P. The liver: a special case in transplantation tolerance. *Semin Liver Dis* 2007;27(2):194-213.
362. Sun J, Sheil AG, Wang C, Wang L, Rokahr K, Sharland A et al. Tolerance to rat liver allografts: IV. Acceptance depends on the quantity of donor tissue and on donor leukocytes. *Transplantation* 1996;62(12):1725-1730.
363. Bishop GA, Sun J, Sheil AG, McCaughan GW. High-dose/activation-associated tolerance: a mechanism for allograft tolerance. *Transplantation* 1997;64(10):1377-1382.
364. Bishop GA, McCaughan GW. Immune activation is required for the induction of liver allograft tolerance: Implications for immunosuppressive therapy. *Liver Transpl* 2001;7(3):161-172.
365. Sharland A, Yan Y, Wang C, Bowen DG, Sun J, Sheil AG et al. Evidence that apoptosis of activated T cells occurs in spontaneous tolerance of liver allografts and is blocked by manipulations which break tolerance. *Transplantation* 1999;68(11):1736-1745.
366. Demetris AJ, Murase N, Starzl TE. Donor dendritic cells after liver and heart allotransplantation under short-term immunosuppression. *Lancet* 1992;339(8809):1610.

367. Demetris AJ, Murase N, Fujisaki S, Fung JJ, Rao AS, Starzl TE. Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. *Transplantation Proceedings* 1993;25(6):3337-3344.
368. Zhuang Q, Lakkis FG. Dendritic cells and innate immunity in kidney transplantation. *Kidney Int* 2015;87(4):712-718.
369. Nakayama M. Antigen Presentation by MHC-Dressed Cells. *Front Immunol* 2014;5:672.
370. Castellanea A, Sumpter TL, Chen L, Tokita D, Thomson AW. NOD2 ligation subverts IFN- α production by liver plasmacytoid dendritic cells and inhibits their T cell allostimulatory activity via B7-H1 up-regulation. *J Immunol* 2009;183(11):6922-6932.
371. Lai WK, Curbishley SM, Goddard S, Alabraba E, Shaw J, Youster J et al. Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function. *J Hepatol* 2007;47(3):338-347.
372. Lau DT, Fish PM, Sinha M, Owen DM, Lemon SM, Gale M, Jr. Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients. *Hepatology* 2008;47(3):799-809.
373. Feng Z, Li Y, McKnight KL, Hensley L, Lanford RE, Walker CM et al. Human pDCs preferentially sense enveloped hepatitis A virions. *J Clin Invest* 2015;125(1):169-176.
374. Behrens EM, Canna SW, Slade K, Rao S, Kreiger PA, Paessler M et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. *J Clin Invest* 2011;121(6):2264-2277.
375. Ebrahimkhani MR, Mohar I, Crispe IN. Cross-presentation of antigen by diverse subsets of murine liver cells. *Hepatology* 2011;54(4):1379-1387.
376. Wong YC, Tay SS, McCaughan GW, Bowen DG, Bertolino P. Immune outcomes in the liver: is CD8 T cell fate determined by the environment? *J Hepatol* 2015.
377. Benseler V, Warren A, Vo M, Holz LE, Tay SS, Le Couteur DG et al. Hepatocyte entry leads to degradation of autoreactive CD8 T cells. *Proc Natl Acad Sci U S A* 2011;108(40):16735-16740.
378. Holz LE, Benseler V, Bowen DG, Bouillet P, Strasser A, O'Reilly L et al. Intrahepatic murine CD8 T-cell activation associates with a distinct phenotype leading to Bim-dependent death. *Gastroenterology* 2008;135(3):989-997.
379. Tay SS, Wong YC, Roediger B, Sierro F, Lu B, McDonald DM et al. Intrahepatic activation of naive CD4+ T cells by liver-resident phagocytic cells. *J Immunol* 2014;193(5):2087-2095.
380. Randolph GJ, Beaulieu S, Lebecque S, Steinman RM, Muller WA. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. *Science* 1998;282(5388):480-483.
381. Liaskou E, Zimmermann HW, Li KK, Oo YH, Suresh S, Stamataki Z et al. Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics. *Hepatology* 2013;57(1):385-398.
382. Hume DA, Mabbott N, Raza S, Freeman TC. Can DCs be distinguished from macrophages by molecular signatures? *Nat Immunol* 2013;14(3):187-189.
383. Stables MJ, Shah S, Camon EB, Lovering RC, Newson J, Bystrom J et al. Transcriptomic analyses of murine resolution-phase macrophages. *Blood* 2011;118(26):e192-208.
384. Tamoutounour S, Williams M, Montanana Sanchis F, Liu H, Terhorst D, Malosse C et al. Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. *Immunity* 2013;39(5):925-938.
385. Sleyster EC, Knook DL. Relation between localization and function of rat liver Kupffer cells. *Lab Invest* 1982;47(5):484-490.
386. Bouwens L, Baekeland M, De Zanger R, Wisse E. Quantitation, tissue distribution and proliferation kinetics of Kupffer cells in normal rat liver. *Hepatology* 1986;6(4):718-722.
387. Naito M, Hasegawa G, Ebe Y, Yamamoto T. Differentiation and function of Kupffer cells. *Med Electron Microsc* 2004;37(1):16-28.

388. McCuskey RS, McCuskey PA. Fine structure and function of Kupffer cells. *J Electron Microscop* 1990;14(3):237-246.
389. Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. *Science* 2012;336(6077):86-90.
390. Naito M, Hasegawa G, Takahashi K. Development, differentiation, and maturation of Kupffer cells. *Microsc Res Tech* 1997;39(4):350-364.
391. Gosselin D, Link VM, Romanoski CE, Fonseca GJ, Eichenfield DZ, Spann NJ et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. *Cell* 2014;159(6):1327-1340.
392. Lee WY, Moriarty TJ, Wong CH, Zhou H, Strieter RM, van Rooijen N et al. An intravascular immune response to *Borrelia burgdorferi* involves Kupffer cells and iNKT cells. *Nat Immunol* 2010;11(4):295-302.
393. Egen JG, Rothfuchs AG, Feng CG, Winter N, Sher A, Germain RN. Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. *Immunity* 2008;28(2):271-284.
394. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. *Science* 2011;332(6035):1284-1288.
395. Widmann JJ, Fahimi HD. Proliferation of mononuclear phagocytes (Kupffer cells) and endothelial cells in regenerating rat liver. A light and electron microscopic cytochemical study. *Am J Pathol* 1975;80(3):349-366.
396. Yamada M, Naito M, Takahashi K. Kupffer cell proliferation and glucan-induced granuloma formation in mice depleted of blood monocytes by strontium-89. *J Leukoc Biol* 1990;47(3):195-205.
397. Yona S, Kim KW, Wolf Y, Mildner A, Varol D, Breker M et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. *Immunity* 2013;38(1):79-91.
398. Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. *Immunity* 2013;38(4):792-804.
399. Sieweke MH, Allen JE. Beyond stem cells: self-renewal of differentiated macrophages. *Science* 2013;342(6161):1242974.
400. Gomez Perdiguero E, Klapproth K, Schulz C, Busch K, Azzoni E, Crozet L et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. *Nature* 2015;518(7540):547-551.
401. Elvevold K, Smedsrød B, Martinez I. The liver sinusoidal endothelial cell: a cell type of controversial and confusing identity. *Am J Physiol Gastrointest Liver Physiol* 2008;294(2):G391-400.
402. Majno G, Joris I. Exploring the Reticuloendothelial System. In: *Cells, Tissues, and Disease*. 2nd ed. New York: Oxford University Press, 2004: 314-321.
403. Terpstra V, van Berkel TJ. Scavenger receptors on liver Kupffer cells mediate the in vivo uptake of oxidatively damaged red blood cells in mice. *Blood* 2000;95(6):2157-2163.
404. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK et al. Identification of the haemoglobin scavenger receptor. *Nature* 2001;409(6817):198-201.
405. Bogers WM, Stad RK, Van Es LA, Daha MR. Both Kupffer cells and liver endothelial cells play an important role in the clearance of IgA and IgG immune complexes. [Review]. *Research in Immunology* 1992;143(2):219-224.
406. Helmy KY, Katschke KJ, Jr., Gorgani NN, Kljavin NM, Elliott JM, Diehl L et al. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. *Cell* 2006;124(5):915-927.
407. Wong CH, Jenne CN, Petri B, Chrobok NL, Kubes P. Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. *Nat Immunol* 2013;14(8):785-792.

408. Holub M, Cheng CW, Mott S, Wintermeyer P, van Rooijen N, Gregory SH. Neutrophils sequestered in the liver suppress the proinflammatory response of Kupffer cells to systemic bacterial infection. *J Immunol* 2009;183(5):3309-3316.
409. Gordy C, Pua H, Sempowski GD, He YW. Regulation of steady-state neutrophil homeostasis by macrophages. *Blood* 2011;117(2):618-629.
410. Gregory SH, Wing EJ. Neutrophil-Kupffer cell interaction: a critical component of host defenses to systemic bacterial infections. *J Leukoc Biol* 2002;72(2):239-248.
411. Hardonk MJ, Dijkhuis FW, Grond J, Koudstaal J, Poppema S. Evidence for a migratory capability of rat Kupffer cells to portal tracts and hepatic lymph nodes. *Virchows Arch B Cell Pathol Incl Mol Pathol* 1986;51(5):429-442.
412. Gugenheim J, Le Thai B, Rouger P, Gigou M, Gane P, Vial MC et al. Relationship between the liver and lymphocytotoxic alloantibodies in inbred rats. Specific absorption by nonparenchymal liver cells. *Transplantation* 1988;45(2):474-478.
413. Gugenheim J, Amorosa L, Gigou M, Fabiani B, Rouger P, Gane P et al. Specific absorption of lymphocytotoxic alloantibodies by the liver in inbred rats. *Transplantation* 1990;50(2):309-313.
414. Klein I, Cornejo JC, Polakos NK, John B, Wuensch SA, Topham DJ et al. Kupffer cell heterogeneity: functional properties of bone marrow derived and sessile hepatic macrophages. *Blood* 2007;110(12):4077-4085.
415. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. *Science* 2010;327(5966):656-661.
416. Lefkowitz JH, Haythe JH, Regent N. Kupffer cell aggregation and perivenular distribution in steatohepatitis. *Mod Pathol* 2002;15(7):699-704.
417. Zani IA, Stephen SL, Mughal NA, Russell D, Homer-Vanniasinkam S, Wheatcroft SB et al. Scavenger receptor structure and function in health and disease. *Cells* 2015;4(2):178-201.
418. Ramprasad MP, Terpstra V, Kondratenko N, Quehenberger O, Steinberg D. Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. *Proc Natl Acad Sci U S A* 1996;93(25):14833-14838.
419. Kurushima H, Ramprasad M, Kondratenko N, Foster DM, Quehenberger O, Steinberg D. Surface expression and rapid internalization of macrosialin (mouse CD68) on elicited mouse peritoneal macrophages. *J Leukoc Biol* 2000;67(1):104-108.
420. Gottfried E, Kunz-Schughart LA, Weber A, Rehli M, Peuker A, Muller A et al. Expression of CD68 in non-myeloid cell types. *Scand J Immunol* 2008;67(5):453-463.
421. Kunisch E, Fuhrmann R, Roth A, Winter R, Lungershausen W, Kinne RW. Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry. *Ann Rheum Dis* 2004;63(7):774-784.
422. Falini B, Flenghi L, Pileri S, Gambacorta M, Bigerna B, Durkop H et al. PG-M1: a new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule. *Am J Pathol* 1993;142(5):1359-1372.
423. Lau SK, Chu PG, Weiss LM. CD163: a specific marker of macrophages in paraffin-embedded tissue samples. *Am J Clin Pathol* 2004;122(5):794-801.
424. Hume DA, Allan W, Hogan PG, Doe WF. Immunohistochemical characterisation of macrophages in human liver and gastrointestinal tract: expression of CD4, HLA-DR, OKM1, and the mature macrophage marker 25F9 in normal and diseased tissue. *J Leukoc Biol* 1987;42(5):474-484.
425. Tomita M, Yamamoto K, Kobashi H, Ohmoto M, Tsuji T. Immunohistochemical phenotyping of liver macrophages in normal and diseased human liver. *Hepatology* 1994;20(2):317-325.
426. Tuijnman WB, Van Wichen DF, Schuurman HJ. Tissue distribution of human IgG Fc receptors CD16, CD32 and CD64: an immunohistochemical study. *APMIS* 1993;101(4):319-329.
427. Jakubzick C, Gautier EL, Gibbings SL, Sojka DK, Schlitzer A, Johnson TE et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. *Immunity* 2013;39(3):599-610.

428. Ikarashi M, Nakashima H, Kinoshita M, Sato A, Nakashima M, Miyazaki H et al. Distinct development and functions of resident and recruited liver Kupffer cells/macrophages. *J Leukoc Biol* 2013;94(6):1325-1336.
429. Xue Z, Ge Z, Zhang K, Sun R, Yang J, Han R et al. Embelin suppresses dendritic cell functions and limits autoimmune encephalomyelitis through the TGF-beta/beta-catenin and STAT3 signaling pathways. *Mol Neurobiol* 2014;49(2):1087-1101.
430. Ingersoll MA, Spanbroek R, Lottaz C, Gautier EL, Frankenberger M, Hoffmann R et al. Comparison of gene expression profiles between human and mouse monocyte subsets. *Blood* 2010;115(3):e10-19.
431. Bernsmeier C, Pop OT, Singanayagam A, Triantafyllou E, Patel VC, Weston CJ et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK. *Gastroenterology* 2015;148(3):603-615 e614.
432. Jassem W, Koo DD, Cerundolo L, Rela M, Heaton ND, Fuggle SV. Leukocyte infiltration and inflammatory antigen expression in cadaveric and living-donor livers before transplant. *Transplantation* 2003;75(12):2001-2007.
433. Dominguez-Soto A, Aragoneses-Fenoll L, Gomez-Aguado F, Corcuera MT, Claria J, Garcia-Monzon C et al. The pathogen receptor liver and lymph node sinusoidal endothelial cell C-type lectin is expressed in human Kupffer cells and regulated by PU.1. *Hepatology* 2009;49(1):287-296.
434. Soilleux EJ, Morris LS, Rushbrook S, Lee B, Coleman N. Expression of human immunodeficiency virus (HIV)-binding lectin DC-SIGNR: Consequences for HIV infection and immunity. *Hum Pathol* 2002;33(6):652-659.
435. Hancock WW, Zola H, Atkins RC. Antigenic heterogeneity of human mononuclear phagocytes: immunohistologic analysis using monoclonal antibodies. *Blood* 1983;62(6):1271-1279.
436. Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C, Zernecke A et al. Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. *PLoS One* 2010;5(6):e11049.
437. Afford SC, Randhawa S, Eliopoulos AG, Hubscher SG, Young LS, Adams DH. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface fas ligand expression and amplifies fas-mediated hepatocyte death during allograft rejection. *J Exp Med* 1999;189(2):441-446.
438. Bartlett AS, McCall JL, Ameratunga R, Yeong ML, Gane E, Munn SR. Analysis of intra-graft gene and protein expression of the costimulatory molecules, CD80, CD86 and CD154, in orthotopic liver transplant recipients. *Am J Transplant* 2003;3(11):1363-1368.
439. Kobayashi T, Sato Y, Yamamoto S, Takeishi T, Hirano K, Watanabe T et al. Augmentation of heme oxygenase-1 expression in the graft immediately after implantation in adult living-donor liver transplantation. *Transplantation* 2005;79(8):977-980.
440. Martinez FO, Helming L, Milde R, Varin A, Melgert BN, Draijer C et al. Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. *Blood* 2013;121(9):e57-69.
441. Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, Kayal S et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. *Science (New York, NY)* 2007;317(5838):666-670.
442. Ziegler-Heitbrock L. Monocyte subsets in man and other species. *Cell Immunol* 2014;289(1-2):135-139.
443. Zimmermann HW, Bruns T, Weston CJ, Curbishley SM, Liaskou E, Li KK et al. Bidirectional transendothelial migration of monocytes across hepatic sinusoidal endothelium shapes monocyte differentiation and regulates the balance between immunity and tolerance in liver. *Hepatology (Baltimore, Md)* 2015.
444. Aspinall AI, Curbishley SM, Lalor PF, Weston CJ, Blahova M, Liaskou E et al. CX(3)CR1 and vascular adhesion protein-1-dependent recruitment of CD16(+) monocytes across human liver sinusoidal endothelium. *Hepatology (Baltimore, Md)* 2010;51(6):2030-2039.

445. Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, Senechal B et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. *Immunity* 2010;33(3):375-386.
446. Carlin LM, Stamatiades EG, Auffray C, Hanna RN, Glover L, Vizcay-Barrena G et al. Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. *Cell* 2013;153(2):362-375.
447. Matsuno K, Ezaki T, Kudo S, Uehara Y. A life stage of particle-laden rat dendritic cells in vivo: their terminal division, active phagocytosis, and translocation from the liver to the draining lymph. *The Journal of experimental medicine* 1996;183(4):1865-1878.
448. Wong T, Nouri-Aria KT, Devlin J, Portmann B, Williams R. Tolerance and latent cellular rejection in long-term liver transplant recipients. *Hepatology* 1998;28(2):443-449.
449. Adams DH, Ju C, Ramaiah SK, Uetrecht J, Jaeschke H. Mechanisms of immune-mediated liver injury. *Toxicol Sci* 2010;115(2):307-321.
450. Garcia-Monzon C, Sanchez-Madrid F, Garcia-Buey L, Garcia-Arroyo A, Garcia-Sanchez A, Moreno-Otero R. Vascular adhesion molecule expression in viral chronic hepatitis: evidence of neoangiogenesis in portal tracts. *Gastroenterology* 1995;108(1):231-241.
451. Eckert C, Klein N, Kornek M, Lukacs-Kornek V. The complex myeloid network of the liver with diverse functional capacity at steady state and in inflammation. *Front Immunol* 2015;6:179.
452. Baeck C, Wei X, Bartneck M, Fech V, Heymann F, Gassler N et al. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. *Hepatology* 2014;59(3):1060-1072.
453. Holt MP, Cheng L, Ju C. Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury. *J Leukoc Biol* 2008;84(6):1410-1421.
454. Morias Y, Abels C, Laoui D, Van Overmeire E, Guillemins M, Schouppe E et al. Ly6C-Monocytes Regulate Parasite-Induced Liver Inflammation by Inducing the Differentiation of Pathogenic Ly6C+ Monocytes into Macrophages. *PLoS Pathog* 2015;11(5):e1004873.
455. Demetris AJ. Central venulitis in liver allografts: considerations of differential diagnosis. *Hepatology* 2001;33(5):1329-1330.
456. Demetris AJ, Seaberg EC, Batts KP, Ferrell LD, Ludwig J, Markin RS et al. Reliability and predictive value of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database nomenclature and grading system for cellular rejection of liver allografts. *Hepatology* 1995;21(2):408-416.
457. Sebah M, Debette M, Samuel D, Emile JF, Falissard B, Cailliez V et al. "Silent" presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection. *Hepatology* 1999;30(5):1144-1150.
458. Quaglia AF, Del Vecchio Blanco G, Greaves R, Burroughs AK, Dhillon AP. Development of ductopenic liver allograft rejection includes a "hepatic" phase prior to duct loss. *J Hepatol* 2000;33(5):773-780.
459. Gouw AS, van den Heuvel MC, van den Berg AP, Slooff MJ, de Jong KP, Poppema S. The significance of parenchymal changes of acute cellular rejection in predicting chronic liver graft rejection. *Transplantation* 2002;73(2):243-247.
460. Hubscher SG. Central perivenulitis: a common and potentially important finding in late posttransplant liver biopsies. *Liver Transpl* 2008;14(5):596-600.
461. Siddiqui I, Selzner N, Hafezi-Bakhtiari S, Marquez MA, Adeyi OA. Infiltrative (sinusoidal) and hepatic patterns of injury in acute cellular rejection in liver allograft with clinical implications. *Mod Pathol* 2015.
462. Porter KA. Pathology of the orthotopic homograft and heterograft. In: Starzl TE, (ed). *Experience in Hepatic Transplantation*. Philadelphia: W.B. Saunders, Co, 1969: 422.

463. Kakizoe S, Yanaga K, Starzl TE, Demetris AJ. Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: considerations of preservation and early immunological injury. *Hepatology* 1990;11(6):932-941.
464. Sawada T, Shimizu A, Kubota K, Fuchinoue S, Teraoka S. Lobular damage caused by cellular and humoral immunity in liver allograft rejection. *Clin Transplant* 2005;19(1):110-114.
465. Dankof A, Schmeding M, Morawietz L, Gunther R, Krukemeyer MG, Rudolph B et al. Portal capillary C4d deposits and increased infiltration by macrophages indicate humorally mediated mechanisms in acute cellular liver allograft rejection. *Virchows Arch* 2005;447(1):87-93.
466. Alabraba EB, Lai V, Boon L, Wigmore SJ, Adams DH, Afford SC. Coculture of human liver macrophages and cholangiocytes leads to CD40-dependent apoptosis and cytokine secretion. *Hepatology* 2008;47(2):552-562.
467. de Groen PC, Kephart GM, Gleich GJ, Ludwig J. The eosinophil as an effector cell of the immune response during hepatic allograft rejection. *Hepatology* 1994;20(3):654-662.
468. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. *Nat Rev Immunol* 2013;13(1):9-22.
469. Huang LR, Wohlleber D, Reisinger F, Jenne CN, Cheng RL, Abdullah Z et al. Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. *Nat Immunol* 2013;14(6):574-583.
470. Mackaness GB. THE IMMUNOLOGICAL BASIS OF ACQUIRED CELLULAR RESISTANCE. *J Exp Med* 1964;120:105-120.
471. Mackaness GB. Cellular resistance to infection. *J Exp Med* 1962;116:381-406.
472. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. *F1000Prime Rep* 2014;6:13.
473. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdts S et al. Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity* 2014;41(1):14-20.
474. Hume DA. The Many Alternative Faces of Macrophage Activation. *Front Immunol* 2015;6:370.
475. Ostuni R, Piccolo V, Barozzi I, Polletti S, Termanini A, Bonifacio S et al. Latent enhancers activated by stimulation in differentiated cells. *Cell* 2013;152(1-2):157-171.
476. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. *Immunity* 2014;40(2):274-288.
477. Sudan B, Wacker MA, Wilson ME, Graff JW. A Systematic Approach to Identify Markers of Distinctly Activated Human Macrophages. *Front Immunol* 2015;6:253.
478. Graff JW, Dickson AM, Clay G, McCaffrey AP, Wilson ME. Identifying functional microRNAs in macrophages with polarized phenotypes. *J Biol Chem* 2012;287(26):21816-21825.
479. Cohen HB, Mosser DM. Extrinsic and intrinsic control of macrophage inflammatory responses. *J Leukoc Biol* 2013;94(5):913-919.
480. Cohen HB, Briggs KT, Marino JP, Ravid K, Robson SC, Mosser DM. TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses. *Blood* 2013;122(11):1935-1945.
481. Jin F, Nathan CF, Radzioch D, Ding A. Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor. *Infect Immun* 1998;66(6):2447-2452.
482. Rothlin CV, Carrera-Silva EA, Bosurgi L, Ghosh S. TAM receptor signaling in immune homeostasis. *Annu Rev Immunol* 2015;33:355-391.
483. Karlmark KR, Zimmermann HW, Roderburg C, Gassler N, Wasmuth HE, Luedde T et al. The fractalkine receptor CX(3)CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. *Hepatology* 2010;52(5):1769-1782.

484. Zigmond E, Samia-Grinberg S, Pasmanik-Chor M, Brazowski E, Shibolet O, Halpern Z et al. Infiltrating monocyte-derived macrophages and resident kupffer cells display different ontogeny and functions in acute liver injury. *J Immunol* 2014;193(1):344-353.
485. Camenisch TD, Koller BH, Earp HS, Matsushima GK. A novel receptor tyrosine kinase, Mer, inhibits TNF- α production and lipopolysaccharide-induced endotoxic shock. *J Immunol* 1999;162(6):3498-3503.
486. Schaer CA, Schoedon G, Imhof A, Kurrer MO, Schaer DJ. Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin. *Circ Res* 2006;99(9):943-950.
487. Schaer DJ, Schaer CA, Schoedon G, Imhof A, Kurrer MO. Hemophagocytic macrophages constitute a major compartment of heme oxygenase expression in sepsis. *Eur J Haematol* 2006;77(5):432-436.
488. Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. *Arthritis Rheum* 2007;56(11):3793-3804.
489. Lu G, Zhang R, Geng S, Peng L, Jayaraman P, Chen C et al. Myeloid cell-derived inducible nitric oxide synthase suppresses M1 macrophage polarization. *Nat Commun* 2015;6:6676.
490. Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. *Nature* 2001;411(6834):207-211.
491. Crispe IN, Giannandrea M, Klein I, John B, Sampson B, Wuensch S. Cellular and molecular mechanisms of liver tolerance. *Immunol Rev* 2006;213:101-118.
492. Ma HD, Wang YH, Chang C, Gershwin ME, Lian ZX. The intestinal microbiota and microenvironment in liver. *Autoimmun Rev* 2015;14(3):183-191.
493. Henao-Mejia J, Elinav E, Thaïs CA, Licona-Limon P, Flavell RA. Role of the intestinal microbiome in liver disease. *J Autoimmun* 2013;46:66-73.
494. Nakamoto N, Kanai T. Role of toll-like receptors in immune activation and tolerance in the liver. *Front Immunol* 2014;5:221.
495. You Q, Cheng L, Kedl RM, Ju C. Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. *Hepatology* 2008;48(3):978-990.
496. Corbitt N, Kimura S, Isse K, Specht S, Chedwick L, Rosborough BR et al. Gut bacteria drive Kupffer cell expansion via MAMP-mediated ICAM-1 induction on sinusoidal endothelium and influence preservation-reperfusion injury after orthotopic liver transplantation. *Am J Pathol* 2013;182(1):180-191.
497. Mastoridis S, Martinez-Llordella M, Sanchez-Fueyo A. Emergent Transcriptomic Technologies and Their Role in the Discovery of Biomarkers of Liver Transplant Tolerance. *Front Immunol* 2015;6:304.
498. Bishop GA, Ierino FL, Sharland AF, Hall BM, Alexander SI, Sandrin MS et al. Approaching the Promise of Operational Tolerance in Clinical Transplantation. *Transplantation* 2011;91(10):1065-1074.
499. Benseler V, Tay SS, Bowen DG, Bertolino P. Role of the hepatic parenchyma in liver transplant tolerance: a paradigm revisited. *Dig Dis* 2011;29(4):391-401.
500. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism, and graft acceptance. *Lancet* 1992;339(8809):1579-1582.
501. Pender MP. Activation-induced apoptosis of autoreactive and alloreactive T lymphocytes in the target organ as a major mechanism of tolerance. *Immunol Cell Biol* 1999;77(3):216-223.
502. Bohne F, Londoño MC, Benítez C, Miquel R, Martínez-Llordella M, Russo C et al. HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans. *Sci Transl Med* 2014;6(242):242ra281.

503. Benitez C, Londono MC, Miquel R, Manzia TM, Abraldes JG, Lozano JJ et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. *Hepatology* 2013.
504. Bohne F, Martinez-Llordella M, Lozano JJ, Miquel R, Benitez C, Londono MC et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. *The Journal of clinical investigation* 2012;122(1):368-382.
505. Castillo-Rama M, Sebah M, Sasatomi E, Randhawa P, Isse K, Salgarkar AD et al. "Plasma Cell Hepatitis" in Liver Allografts: Identification and Characterization of an IgG4-Rich Cohort. *Am J Transplant* 2013;13(11):2966-2977.
506. Kamada N. The immunology of experimental liver transplantation in the rat. *Immunology* 1985;55(3):369-389.
507. Calne RY, White HJO, Yoffa DE, Maginn RR, Binns RM, Samuel JR et al. Observations of orthotopic liver transplantation in the pig. *British Medical Journal* 1967;2:478-480.
508. Brent L. Immunoregulation: The Search for the Holy Grail. In: Brent L, (ed). *A History of Transplant Immunology*. London: Academic Press, 1997: 230-304.
509. Terasaki PI. Humoral theory of transplantation. *Am J Transplant* 2003;3(6):665-673.
510. Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R et al. Type I and type II Fc receptors regulate innate and adaptive immunity. *Nat Immunol* 2014;15(8):707-716.
511. Wang TT, Ravetch JV. Immune complexes: not just an innocent bystander in chronic viral infection. *Immunity* 2015;42(2):213-215.
512. Demetris AJ, Nakamura K, Yagihashi A, Iwaki Y, Takaya S, Hartman GG et al. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. *Hepatology* 1992;16(3):671-681.
513. O'Leary JG, Michelle Shiller S, Bellamy C, Nalesnik MA, Kaneku H, Jennings LW et al. Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features. *Liver Transpl* 2014;20(10):1244-1255.
514. Feng S, Bucuvalas J, Demetris A, Spain K, Mazariegos G, Burrell B et al. Deceased Donor and Class II Donor Specific Antibody Predict Interface Activity While Increased Age at Time of Biopsy Predicts Fibrosis in Long-Term Pediatric Liver Allografts With Normal Liver Tests: iWITH Clinical Trial [abstract]. . In. *Am J Transplant*. 2015; 15 (suppl 3). 2015.
515. Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. *Jama* 2012;307(3):283-293.
516. Howell J, Gow P, Angus P, Visvanathan K. Role of toll-like receptors in liver transplantation. *Liver Transpl* 2014;20(3):270-280.
517. Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. *World J Gastroenterol* 2006;12(46):7413-7420.
518. Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. *Liver Int* 2006;26(10):1175-1186.
519. Tsung A, Hoffman RA, Izuishi K, Critchlow ND, Nakao A, Chan MH et al. Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. *J Immunol* 2005;175(11):7661-7668.
520. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. *J Exp Med* 2005;201(7):1135-1143.
521. Maemura K, Zheng Q, Wada T, Ozaki M, Takao S, Aikou T et al. Reactive oxygen species are essential mediators in antigen presentation by Kupffer cells. *Immunol Cell Biol* 2005;83(4):336-343.
522. Kwekkeboom J, Kuijpers MA, Bruyneel B, Mancham S, De Baar-Heesakkers E, Ijzermans JN et al. Expression of CD80 on Kupffer cells is enhanced in cadaveric liver transplants. *Clin Exp Immunol* 2003;132(2):345-351.
523. Batchelor JR. The use of enhancement in studying tumor antigens. *Cancer Res* 1968;28(7):1410-1414.

524. Accolla RS, Lombardo L, Abdallah R, Raval G, Forlani G, Tosi G. Boosting the MHC Class II-Restricted Tumor Antigen Presentation to CD4+ T Helper Cells: A Critical Issue for Triggering Protective Immunity and Re-Orienting the Tumor Microenvironment Toward an Anti-Tumor State. *Front Oncol* 2014;4:32.
525. Geissmann F, Cameron TO, Sidobre S, Manlongat N, Kronenberg M, Briskin MJ et al. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. *PLoS Biol* 2005;3(4):e113.
526. Wehr A, Baeck C, Heymann F, Niemietz PM, Hammerich L, Martin C et al. Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis. *J Immunol* 2013;190(10):5226-5236.
527. Ballardini G, Mirakian R, Bianchi FB, Pisi E, Doniach D, Bottazzo GF. Aberrant expression of HLA-DR antigens on bile duct epithelium in primary biliary cirrhosis: relevance to pathogenesis. *Lancet* 1984;2(8410):1009-1013.
528. Hubscher SG, Adams DH, Elias E. Beta-2-microglobulin expression in the liver after liver transplantation. *J Clin Pathol* 1988;41(10):1049-1057.
529. Rouger P, Gugenheim J, Gane P, Capron-Landereau M, Michel F, Reynes M et al. Distribution of the MHC antigens after liver transplantation: relationship with biochemical and histological parameters. *Clin Exp Immunol* 1990;80(3):404-408.

Figure `1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Tables and Figures

Table 1. Expression of ABH and MHC antigens in human liver under normal circumstances versus inflammatory conditions (normal → inflamed liver).

Antigen	HC	BEC	LSEC	KC	SC	HA/PV/CV Endothelium	DC	Portal Microvascular Endo.
AB	–	+	+	–	–	+++	–	++
H	–	++	+	–	–	+++	–	++
MHC A,B	+/- → +	+++	++	++	+→++	++	++	++
MHC DR	- → +	- → ++	- → ++	+→++	+→++	-→++	++→+++	+/- (variable)→+++
MHC DP	- → +	- → +	- → +	+→++	-→+/-	-→++	++→+++	+/-→++
MHC DQ	- → -	-/+ → -	-/+ → –	+→++	-→+/-	-→+/-	++→+++	-/+→++

Abbreviations: BEC: biliary epithelial cells; CV: central vein; DC: dendritic cells; HA: hepatic artery; HC: hepatocytes; KC: Kupffer cells; LSEC: liver sinusoidal endothelial cells; PV: portal vein; SC: stellate cells; Data compiled from references ((202-207, 210-215, 226, 527-529)). More work is needed in study class II expression in specific compartments.